Official Title:          A Randomized, Double-Blind, Vehicle-Controlled Study 
to Evaluate the Mechanism of Action of Ruxolitinib Cream for 
Vitiligo  (TRuE-V MOA)
Study ID: [REMOVED] 
Document Date: Original Protocol: 03-Ma rch-2021 
Incyte Corporation   Page 1 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898 CONFIDENTIAL  Clinical Study Protocol  
TITLE PAGE  
INCB 18424 -214 
A Randomized, Double -Blind, Vehicle -Controlled Study to Evaluate the 
Mechanism of Action of  Ruxolitinib Cream for Vitiligo  
(TRuE -V MOA)  
Product:  Ruxolitinib Cream  
IND Number:   
EudraCT Number:  2021 -000361 -32 
Phase of Study : 2 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, Delaware, USA  19803  
Original  Protocol:  03 MAR  2021  
This study will be performed in accordance with ethical principles that have their origin in the Declaration of 
Helsinki and conducted in a dherence to the study Protocol , applicable  Good Clinical Practices , and applicable laws 
and country -specific regulations in which the study is being conducted . 
The information in this document is confidential .  No part of this information may be duplicated, referenced, or 
transmitted in any form or by any means (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written  consent . 

Incyte Corporation   Page 2 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  INVESTIGATOR 'S AGREEMENT  
I have read the INCB 18424 -214 Protocol  (dated  03 MAR  2021 ) and agree to conduct the study 
as outlined .  I agree to maintain the confidentiality of all information received or developed in 
connection with this Protocol . 
 
 
   
(Printed Name of Investigator)    
   
   
(Signature of Investigator)   (Date)  
Incyte Corporation   Page 3 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...1 
INVESTIGATOR'S AGREE MENT  ................................ ................................ ................................ 2 
TABLE OF C ONTENTS  ................................ ................................ ................................ ................. 3 
LIST OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 10 
2. INTRODUCTION  ................................ ................................ ................................ ......17 
2.1. Background  ................................ ................................ ................................ ................. 17 
2.2. Study Rationale  ................................ ................................ ................................ ........... 18 
2.2.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 18 
2.2.2.  Justification for Dose  ................................ ................................ ................................ ..19 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 20 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 21 
4. STUDY DESIGN  ................................ ................................ ................................ .......22 
4.1. Overall Desig n ................................ ................................ ................................ ............ 22 
4.2. Overall Study Duration  ................................ ................................ ............................... 22 
4.3. Study Termination  ................................ ................................ ................................ ......23 
5. STUDY POPULATION  ................................ ................................ ............................. 23 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 23 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......24 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 26 
5.4. Screen Failures  ................................ ................................ ................................ ............ 26 
5.5. Replacement of Participants  ................................ ................................ ....................... 26 
6. STUDY TREATMENT  ................................ ................................ .............................. 27 
6.1. Study Treatments Administered  ................................ ................................ ................. 27 
6.1.1.  Application During the Double -Blind, Vehicle -Controlled Treatment Period  .......... 28 
6.1.2.  Application During the Open -Label Treatme nt Extension Period  ............................. 28 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 29 
6.3. Measures to Minimize Bias:  Randomization and Blinding  ................................ .......30 
6.4. Study Treatment Compliance  ................................ ................................ ..................... 30 
6.5. Dose Modifications  ................................ ................................ ................................ .....30 
6.5.1.  Criteria and Procedures for Dose Interruptions and Adjustments of Study 
Drug  ................................ ................................ ................................ ............................ 30 
Incyte Corporation   Page 4 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  6.5.2.  Criteria for Permanent Discontinuation of Study Drug  ................................ .............. 31 
6.6. Concomitant Medications and Procedures  ................................ ................................ .32 
6.6.1.  Permitted Medications and Procedures  ................................ ................................ ......32 
6.6.2.  Restricted Medications and Procedures  ................................ ................................ ......32 
6.6.3.  Prohibited Medications and Procedures  ................................ ................................ .....33 
6.7. Treatment After the End of the Study  ................................ ................................ ......... 33 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT 
WITHDRAWAL  ................................ ................................ ................................ ........ 34 
7.1. Discontinuation of Study Treatment  ................................ ................................ ........... 34 
7.1.1.  Reasons for Discontinuation  ................................ ................................ ....................... 34 
7.1.2.  Discontinuation Procedures  ................................ ................................ ........................ 34 
7.2. Participant Withdrawal From the Study  ................................ ................................ .....35 
7.3. Lost to Follow -Up................................ ................................ ................................ .......35 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 36 
8.1. Administrative and General Procedures  ................................ ................................ .....36 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 36 
8.1.2.  Screening Procedures  ................................ ................................ ................................ ..37 
8.1.3.  Interactive Response Technology Procedure  ................................ .............................. 37 
8.1.4.  Distribution of Reminder Cards and Diaries  ................................ .............................. 37 
8.1.5.  Demography and Medical History  ................................ ................................ .............. 38 
8.1.5.1.  Demographics and General Medical History  ................................ ............................. 38 
8.1.5.2.  Disease Characteristics and Treatment History  ................................ .......................... 38 
 38 
 38 
 .38 
 38 
8.3. Safety Assessments  ................................ ................................ ................................ .....39 
8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 39 
8.3.2.  Physical Examinations  ................................ ................................ ................................ 40 
8.3.3. Vital Signs  ................................ ................................ ................................ .................. 40 
8.3.4.  Electrocardiograms  ................................ ................................ ................................ .....40 
8.3.5.  Laboratory Assessments  ................................ ................................ ............................. 41 
8.3.5.1. Pregnancy Testing  ................................ ................................ ................................ ......42 

Incyte Corporation   Page 5 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8.3.5.2.  Serology  ................................ ................................ ................................ ...................... 42 
8.4. 42 
8.5. Pharmacodynamic and Translational Assessments  ................................ .................... 42 
8.5.1.  Skin Biopsy  ................................ ................................ ................................ ................. 43 
8.5.2.  43 
8.5.3.  Immunohistology and Other Imaging Techniques  ................................ ..................... 44 
8.6. Unscheduled Visits  ................................ ................................ ................................ .....44 
8.7. End o f Treatment and/or Early Termination  ................................ .............................. 44 
8.8. Safety Follow -Up ................................ ................................ ................................ ........ 44 
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  ...................... 45 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 45 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 46 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... 47 
9.4. Reporting of Serious Adverse Events  ................................ ................................ ......... 49 
9.5. Events of Clinical Interest  ................................ ................................ .......................... 50 
9.5.1.  Adverse Events of Special Interest  ................................ ................................ ............. 50 
9.6. Emergency Unblinding of Treatment Assignment  ................................ ..................... 50 
9.7. Pregnancy  ................................ ................................ ................................ ................... 51 
9.8. Warnings and Precautions  ................................ ................................ .......................... 51 
9.9. Product Complaints  ................................ ................................ ................................ ....51 
9.10.  Treatment of Overdose  ................................ ................................ ............................... 52 
10. STATISTICS  ................................ ................................ ................................ .............. 52 
10.1.  Sample Size Determination  ................................ ................................ ........................ 52 
10.2. Populations for Analysis  ................................ ................................ ............................. 52 
10.3.  Level of Significance  ................................ ................................ ................................ ..53 
10.4.  Data Handling Definitions and Conventions  ................................ .............................. 53 
10.4.1.  Day 1  ................................ ................................ ................................ ........................... 53 
10.4.2.  Study Day  ................................ ................................ ................................ ................... 53 
10.4.3.  Baseline Value  ................................ ................................ ................................ ............ 53 
10.4.4.  Handling of Missing and Incomplete Data  ................................ ................................ .53 
10.5.  Statistical Analyses  ................................ ................................ ................................ .....53 

Incyte Corporation   Page 6 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  10.5.1.  Baseline, Demographics, Disease History, and Prior and Concomitant 
Medication  ................................ ................................ ................................ .................. 53 
10.5.2.  Disposition of Participants  ................................ ................................ .......................... 53 
10.5.3.  Exposure and Study Drug Compliance  ................................ ................................ .......54 
 54 
10.5.5.  Safety Analysis  ................................ ................................ ................................ ........... 54 
10.5.6.  Translational Analyses  ................................ ................................ ................................ 55 
 55 
10.6.  Interim Analysis  ................................ ................................ ................................ .......... 55 
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..55 
11.1.  Investigator Responsibilities  ................................ ................................ ....................... 55 
11.2.  Data Management  ................................ ................................ ................................ .......56 
11.3.  Data Privacy and Confidentiality of Study Records  ................................ ................... 58 
11.4.  Financial Disclosure  ................................ ................................ ................................ ...58 
11.5.  Publication Policy  ................................ ................................ ................................ .......59 
11.6.  Study and Site Closure ................................ ................................ ................................ 59 
12. REFERENCES  ................................ ................................ ................................ ........... 60 
APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  ................................ ............ 61 
APPENDIX  B. WHO CLASSIFICATI ON OF TOPICAL CORTIC OSTEROIDS  ................... 62 
APPENDIX  C. COVID -19 PANDEMIC MI TIGATION STRATEGIES AND 
INSTRUCTIONS  ................................ ................................ ................................ .......63 
APPENDIX  D. PROTOCOL AMENDMENT S UMMARY OF CHANGES  ........................... 65 
 
LIST OF TABL ES 
Table  1: Primary and Secondary Objectives and Endpoints  ................................ ..................... 10 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 10 
Table  3: Schedule of Activities:  Double -Blind, Vehicle -Controlled Treatment Period 
(Day 1 to Week 24)  ................................ ................................ ................................ .....12 
Table  4: Schedule of Act ivities:  Open -Label Treatment Extension (Week 28 to 
Week  52) ................................ ................................ ................................ ..................... 15 
Table  5: Objectives and Endpoints  ................................ ................................ ........................... 21 
Table  6: Study Treatment Information  ................................ ................................ ..................... 27 

Incyte Corporation   Page 7 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  7: Guidelines for Interruption and Restarting of Study Drug  ................................ ......... 31 
Table  8: Required Laboratory Analytes  ................................ ................................ .................... 41 
Table  9: Populations for Analysis  ................................ ................................ ............................. 52 
Table  10: Safety Analyses  ................................ ................................ ................................ .......... 54 
 
LIST OF FIGURES  
Figure  1: Study Design Schema  ................................ ................................ ................................ .11 
 
Incyte Corporation   Page 8 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  LIST OF ABBREVIATION S 
Abbreviations and 
Special Terms  Definition  
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BID twice daily  
BSA  body surface area  
CFR  Code of Federal Regulations  
COVID -19 coronavirus disease 2019  
CTCAE  Common Terminology Criteria for Adverse Events  
CXCL  C-X-C motif chemokine ligand  
DNA  deoxyribonucleic acid  
DSMB  data safety monitoring board 
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EOS  end of study  
EOT  end of treatment  
F-BSA  facial body surface area  
F-VASI  facial Vitiligo Area Scoring Index  
F-VASI50/75  50%/ 75% improvement  in facial Vitiligo Area Scoring Index  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
IB Investigator 's Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
ID identification  
IEC independent ethics committee  
Incyte Corporation   Page 9 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Abbreviations and 
Special Terms  Definition  
IFN-γ interferon gamma  
IRB institutional review board  
IRT interactive response technology  
ITT intent to treat  
JAK Janus kinase  
MedDRA  Medical Dictionary for Regulatory Activities  
MOA  mechanism of action  
PBMC  peripheral blood mononuclear cell  
  
QD once daily  
RNA  ribonucleic acid  
RNAseq  ribonucleic acid sequencing  
RSI reference safety information  
SAE  serious adverse event  
SoA schedule of activities  
SOP standard operating procedure  
SPF sun protection factor  
T4 thyroxine  
T-BSA  total body surface area  
TEAE  treatment -emergent adverse event  
TSH  thyroid -stimulating hormone  
T-VASI  total body Vitiligo Area Scoring Index  
T-VASI 50/75  50%/ 75% improvement in total body Vitiligo Area Scoring Index  
ULN  upper limit of normal  
UV ultraviolet  
VASI  Vitiligo Area Scoring Index  
WHO  World Health Organization  
 

Incyte Corporation   Page 10 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  1. PROTOCOL SUMMARY  
Protocol Title:   A Randomized, Double -Blind, Vehicle -Controlled Study to Evaluate the 
Mechanism of Action of Ruxolitinib Cream for Vitiligo (TRuE -V MOA)  
Protocol Number:   INCB 18424 -214 
Objectives and Endpoints : 
Table  1 presents the primary and secondary objectives and endpoints.  
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the change in immune biomarkers  in 
participants with vitiligo.  • Percentage change from baseline in immune 
biomarkers , including CXCL10 , at Week  4, Week  12, 
and Week 24 . 
Secondary  
• To correlate the change in key serum and skin 
biomarkers of vitiligo to efficacy . • Correlation of  key skin inflammatory biomarkers of 
vitili go in target lesio ns to efficacy readouts at 
Week  12 and Week 24 . 
• To assess the safety and local tolerability of 
ruxolitinib cream.  • The frequency and severity of AEs.  
Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study Phase  Phase 2  
Clinical Indication  Treatment of patients with v itiligo  
Population  Male and female participants aged ≥  18 years  of age  who have nonsegmental vitiligo 
with depigmented areas including  ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA 
on nonfacial areas, and ≥  3 T-VASI.  Total body vitiligo area (facial and nonfacial) 
should not exceed 50% BSA . 
Number of 
Participants  Approximately 60 participants will be randomized 2 :1 (ruxolitinib cream 1.5% 
BID: vehicle  BID). 
Study Design  Randomized, double -blind, vehicle -controlled, with an open -label treatment extension . 
Estimated Duration 
of Study 
Participation  Screening:  Up to 4 2 days. 
Double -blind period:  24 weeks . 
Open -label period:  28 weeks . 
Safety follow -up:  30 days after last application of study drug or last study visit . 
Total:  Up to approximately 63 weeks . 
DSMB  No 
Coordinating 
Principal 
Investigator  To be determined  
Incyte Corporation   Page 11 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Treatment Groups and Duration:  
This is a randomized, double -blind, vehicle -controlled study  with an open -label treatment 
extension period  in adult participants (age ≥  18 years) with nonsegmental vitiligo who have 
depigmented area s including  ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on nonfacial 
areas, and ≥ 3 T -VASI .  Total body involved vi tiligo area (facial and nonfacial) should not 
exceed 50% BSA.  Approximately 60  participants will be randomized 2:1 to receive initial 
double -blind study treatment (ruxolitinib cream 1.5%:vehicle)  administered BID  for 24  weeks  
(see Figure  1).  Participants will be stratified by age (≤  40 years old and >  40 years ol d).  During 
the double -blind treatment period, the participant 's randomized treatment will be applied to 
depigmented areas on the face and body up to 20% T-BSA  (facial and nonfacial) . 
After completion of the Week 24 assessments  from the double -blind treatment period , eligible 
participants will be offered the opportuni ty to continue the study in the 28-week  open -label  
treatment extension period in which all participants  will receive  open -label ruxolitinib cream 
1.5% , administered  BID.  To be eligible for the open -label treatment  extension  period , 
participants must have completed the baseline and Week  24 visit assessments, be compliant with 
study procedures, and not have any safety issues.  The total treated area in the open -label 
treatment extension period should not exceed 20% BSA (facial and nonfacial).  
Figure  1 presents the study design schema.  The SoA is detailed in Table  3 (for the double -blind 
treatment period) and Table  4 (for the open -label treatment extension period).  Adherence to the 
study design requirements, including those specified in the SoA, is essential and required for 
study conduct.  
Figure  1: Study Design Schema  
 
 
 

Incyte Corporation   Page 12 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  3: Schedule of Activities:  Double -Blind, Vehicle -Controlled Treatment Perio d (Day 1  to Week 24)  
Procedure  Screening  Double -Blind, Vehicle -Controlled Treatment  
Notes  Days  
−42 to −1 Day 1  
(Baseline)  Wk 4  
(± 3 d ) Wk 8  
(± 3 d ) Wk 12  
(± 3 d ) Wk 18  
(± 7 d ) Wk 24a 
(EOT1)  
(± 7 d ) 
Administrative procedures   
Informed consent  X        
Contact IRT  X* X X X X X X *Entry of age into the IRT will be required at screening.  
Inclusion and exclusion 
criteria  X X       
Demography  X        
General and disease medical 
history  X        
Prior/concomitant 
medications  X X X X X X X  
Application of study drug at 
site  X X X X X X* At each study visit , starting at Day 1, the participant 
should apply the study drug under direct supervision of the 
site staff.  
*At the Week 24 visit, study drug is only applied by 
participants continuing in the open -label treatment 
extension period.  
Dispense (D) and return (R) 
study drug and 
reminder/ diary cards   D R/D R/D R/D R/D R/D*  All tubes of study drug will be weighed before being 
dispensed.  All returned tubes of study drug will be 
weighed.  
*At the Week 24 visit, study drug and diary cards are only 
dispensed to participants continuing in the open -label  
treatment extension  period.  
Collect study drug and 
collect/review study drug 
diary cards    X X X X X  
Assess compliance    X X X X X  
Incyte Corporation   Page 13 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  3: Schedule of Activities:  Double -Blind, Vehicle -Controlled Treatment Period (Day 1  to Week 24)  (Continued)  
Procedure  Screening  Double -Blind, Vehicle -Controlled Treatment  
Notes  Days  
−42 to −1 Day 1  
(Baseline)  Wk 4  
(± 3 d ) Wk 8  
(± 3 d ) Wk 12  
(± 3 d ) Wk 18  
(± 7 d ) Wk 24a 
(EOT1)  
(± 7 d ) 
Safety assessments   
AE assessment  X X X X X X X  
Comprehensive physical 
examination  X      X  
Targeted physical 
examination   X X X X X  See Section  8.3.2 . 
Vital signs  X X X X X X X  
12-Lead ECG  X       12-Lead ECG performed within 2 months before baseline 
is acceptable.  
 
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X X X X  
Serology  X       Serology includes hepatitis and HIV assessments . 
Thyroid testing  X        
Urinalysis  X        
FSH X*       *FSH is only measured f or confirmation of nonchildbearing 
status of women who are postmenopausal , defined as having 
amenorrhea for at least 12  months without an alternative 
medical cause before screening.  
Pregnancy testing  X* X X X X X X *Female participants of childbearing potential will have a 
serum test at the screening and safety follow -up visits.  A 
urine test will be conducted at all other visits.  A positive 
urine test must be confirmed by a serum test.  

Incyte Corporation   Page 14 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  3: Schedule of Activities:  Double -Blind, Vehicle -Controlled Treatment Period (Day 1  to Week 24)  (Continued)  
Procedure  Screening  Double -Blind, Vehicle -Controlled Treatment  
Notes  Days  
−42 to −1 Day 1  
(Baseline)  Wk 4  
(± 3 d ) Wk 8  
(± 3 d ) Wk 12  
(± 3 d ) Wk 18  
(± 7 d ) Wk 24a 
(EOT1)  
(± 7 d ) 
 translational assessments   
Serum biomarker sampling   X X  X  X  
Skin biopsy :  lesional vitiligo 
skin (identified at baseline 
[Day 1 ])   X   X  X For lesional  skin,  per timep oint will be taken 
from the inside edge of a n active  vitiligo lesion , and the 
sampling area should be entirely contained within lesional 
skin.  
See Section  8.5.1 .  
Skin biopsy:  nonlesional   X      For nonlesional skin,  will be taken at baseline 
(Day 1) from uninvolved skin adjacent  to the lesional area 
selected for biopsy . 
Note:  Unscheduled visits may occur at any time at the investigator 's discretion, and appropriate clinical and laboratory tests may be performed, as clinically indicated.  
a Week 24 is considered the fir st visit of the open -label period.  
 
 

Incyte Corporation   Page 15 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  4: Schedule of Activities:  Open -Label Treatment Extension  (Week 28  to Week  52) 
Procedure  Open -Label Treatment Extension  Safety Follow -Up 
Notes  Wk 28  
(± 7 d ) Wk 40  
(± 7 d ) Wk 52 
(EOT2a) 
(± 7 d ) 30 Days After 
EOT1/EOT2b 
(EOS)  
(+ 7 d) 
Administrative procedures   
Contact IRT  X X X X  
Prior/concomitant medications  X X X X  
Application of  study drug at site  X X   At each study visit, the participant should apply the study drug under direct 
supervision of the site staff.  
Dispense (D) and return (R) study 
drug and reminder/ diary cards  R/D R/D R  All tubes of study drug will be weighed before being  dispensed.  All 
returned tubes of study drug will be weighed.  
Collect study drug and collect/ 
review study drug diary cards  X X X   
Assess compliance  X X X   
Safety assessments   
AE assessment  X X X X  
Comprehensive physical 
examination    X   
Targeted physical examination  X X  X See Section  8.3.2 . 
Vital signs  X X X X  
 
Laboratory assessments   
Hematology and chemistry 
assessments  X X X X  
Pregnancy testing  X X X X* *Female participants of childbearing potential will have a serum test at  the 
screening and safety follow -up visits.  A urine test will be conducted at all 
other visits.  A positive urine test must be confirmed by a serum test.  
 translational assessments  

Incyte Corporation   Page 16 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Table  4: Schedule of Activities:  Open -Label Treatment Extension  (Week 28  to Week 52) (Continued)  
Procedure  Open -Label Treatment Extension  Safety Follow -Up 
Notes  Wk 28  
(± 7 d ) Wk 40  
(± 7 d ) Wk 52  
(EOT2a) 
(± 7 d ) 30 Days After 
EOT1/EOT2b 
(EOS)  
(+ 7 d) 
 translational assessments  (continued)  
Serum biomarker sampling   X X*  *Only for participants who stop treatment before Week 52 and do not 
complete the Week 40 visit.  
Skin biopsy :  lesional vitiligo 
skin (identified at baseline 
[Day 1])  X X*  For lesional skin,  per timepoint will be taken from the inside 
edge of an active vitiligo lesion, and the sampling area should be entirely 
contained within lesional skin.  
See Section  8.5.1 . 
*Only for participant s who stop treatment before W eek 52 and do not 
complete the Week 40 visit.  
Note:  Unscheduled visits may occur at any time at the investigator 's discretion, and appropriate clinical and laboratory tests  may be performed, as clinically indicated . 
a EOT2 assessments should be performed in the event a participant's treatment is stopped before Week 52 at any relevant study v isit before that time.  
b After last application of study drug or last visit.  
 
 

Incyte Corporation   Page 17 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  2. INTRODUCTION  
2.1. Background  
Ruxolitinib cream is a topical formulation of ruxolitinib phosphate under development for the 
treatment of patients  with atopic dermatitis , alopecia areata , plaque psoriasis, and vitiligo.  
Ruxolitinib phosphate is an inhibitor of the JAK family of protein tyrosine kinases .  
Inflammatory cytokines are strongly implicated in the pathogenesis of several dermatologic 
diseases.  Because JAKs serve to translate e xtracellular signals from a number of relevant 
cytokines and growth factors upregulated in inflammatory diseases such as atopic dermatitis , 
alopecia areata , plaque psoriasis, and vitiligo, JAK inhibitors represent potential therapeutic 
agents for these dis ease states ( Howell  et al 2019 ). 
Nonclinical pharmacology, PK, pharmacodynamic , and toxicology data for ruxolitinib cream 
from  in vitro and in  vivo model  syste ms support the use of topically  applied ruxolitinib cream in  
the treatment of patients with atopic dermatitis , psoriasis , vitiligo, and other inflammatory 
diseases of the skin.   Refer to the ruxolitinib cream IB for a summary of findings from the 
nonclinical studies.  
Vitiligo  is an autoimmune disease  that is  characterized by areas of depigmented skin ; it affects 
up to 2% of the global population and is associated with a significantly reduced quality of life 
(Krüger  and Schallreut er 2012 ).  Currently, there are no US FDA -approved treatments for 
vitiligo, and most treatment paradigms rely on the use of corticosteroids, narrowband UV light, 
off-label treat ments, or combination therapy; these t reatmen ts produce unpredictable and 
inconsistent results and are frequently cosmetically unacceptable to the patient.  A treatment that 
produces predictable results and that can be applied by the patient is a n area of high unmet need 
for patients with vitiligo.  
The skin of patients with vitiligo  is characterized by depigmented patches that result from the 
infiltration of affected areas with activated antigen -specific CD8 + T cells that drive melanocyte 
death and disease pathogenesis ( Taïeb  and Picardo  2009 , van den Boorn  et al 2009 ).  
Recruitment of autoreactive CD8+ T cells to melanocytes is me diated by IFN -γ through the 
IFN-γ–induced chemokines CXCL9 and CXCL10, a signaling pathway regulated by JAK1 and 
JAK2 ( Harris  et al 2012 , Rashighi  et al 2014 , Rashighi  and Harris  2015 ).  The interruption of 
IFN-γ signaling via the JAK pathway represents an important therapeutic strategy to evaluate in 
the treatment of vitiligo ( Dina  et al 2019 ).  In a recent randomized, do uble-blind, placebo -
controlled P hase 2 study ( INCB  18424 -211; [STUDY_ID_REMOVED]), ruxolitinib cr eam, a topica l JAK1/2 
inhibitor,  demonstrated efficacy in patients with vitiligo (Rosmarin  et al 2020 ; see also 
Section  2.2.2  for a brief summary of f indings from this study ).  The specific impacts of 
ruxolitinib cream on the biology of melanocytes were not evaluated in this study, but the findings 
warrant an evaluat ion of the effects of ruxolitinib cream on melanocytes and support continued 
clinical development of ruxolitinib cream for the treatment of  patients with  vitiligo.  
Safety findings  from this Phase 2 study and 2 ongoing Phase  3 studies (INCB  18424 -306 and 
INCB 18424 -307) in participants with vitiligo also support continued development of ruxolitinib 
cream for the treatment of patients with this condition .  As of the cutoff date for the ruxolitinib 
cream IB (Edition 9 ), a total of 203  participants with vitiligo have received ruxolitinib cream.  
Incyte Corporation   Page 18 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Safety findings across the 3 vitiligo studies showed  that the majority of participants had good 
local tolerability with use of ruxolitinib cream , there were few application site re actions (all 
Grade 1 or 2), and all SAEs were reported in 1  participant each (ie, there were no patterns of 
SAEs).  
Refer to the ruxolitinib cream IB for a summary of available clinical efficacy and safety data 
from t he vitiligo studies as well as safety data from  ruxolitinib cream clinical studies conducted 
in other disease states.  
2.2. Study Rationale  
Three  studies  have been previously initiated to evaluate  the safety and efficacy of ruxolitinib 
cream in patients with vitiligo:  Phase  2 study INCB  18424 -211, ongoing Phase  3 study 
INCB  18424 -306 (TRuE -V1), and ongoing Phase  3 study INCB  18424 -307 (TRuE -V2);  
.  The purpose of the present study is to provide a more comprehensive evaluation 
than has been undertake n in the previously initiated studies of the MOA  of ruxolitinib  cream  in 
vitiligo.  
2.2.1.  Scientific Rationale for Study Design  
Janus kinases  are intracellular signaling enzymes that act downstream of key proinflammatory 
cytokines implicated in the pathogenesis  of vitiligo .  The safety and efficacy of topical cream 
containing ruxolitinib, a JAK inhibitor, was evaluated in a randomized, double -blind, 
vehicle -controlled Phase  2 study conducted in adults with vitiligo; the study has completed.  
Findings from the Phas e 2 study demonstrated that treatment with ruxolitinib cream was 
associated with substantial repigmentation of vitiligo lesions up to 52 weeks of treatment, and all 
doses were well -tolerated ( Rosmarin  et al 2020 ).  The Phase 2 data suggest that JAK inhibition is 
an effective therapeutic strategy to treat patients with vitiligo.  Two identical Phase  3 studies 
were initiated to  confirm the Phase 2 findings in a larger patient population and are ongoing.  
The objectives o f the current Phase  2 MOA  study are to collect data that will contribute to the 
understanding of immune biomarkers of vitiligo and to further confirm the safety and efficacy of 
ruxolitinib cream in patients with vitiligo.  Skin biopsies, serum , and PBMCs w ill be collected 
over time to further understand the effect of ruxolitinib cream  
 and to assess vario us biomarkers of inflammation.  
The population to be studied comprises adults (≥  18 years of age) with nonsegmental vitiligo  
who have depigmented area s including ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on  
nonfacial a reas, and ≥ 3 T -VASI .  Total body involved vitiligo area (facial and nonfacial) should 
not exceed 50% BSA.   
Partici pants  enrolled in this study will be randomized 2:1 to receive ruxolitinib cream 1.5% BID 
or vehicle BID and treated for 24 weeks in a double -blinded fashion.  After 24 weeks, 
participants  originally randomized to vehicle will switch to active treatment wi th ruxolitinib 
cream.  
 
  Additionally, it is deemed unethical and impractical to deprive patients of 

Incyte Corporation   Page 19 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  effective management of their skin disease for periods extending beyond a maximum of 
6 months.  In the Phase 2 study, up to 56.7% of the population was classified as having 
progressive disease, and long vehicle -controlled periods may have result ed in extension of their 
disease.  The vast majority of clinical studies in chronic nonfatal skin diseases do not use a 
placebo/vehicle arm for longer than 16  weeks.  The proposed 24 week s is thus a compromise 
between the longest acceptable duration of no active treatment (vehicle) and the minimum time 
required to observe a meaningful clinical response to treatment (repigmentation).  Additionally, 
the 2:1 (versus a 1:1) randomization allow s more of the study population to receive active 
treatment for the full duration of the study.  
The 28 -week open -label period is designed to allow participants initially randomized to vehicle 
treatment to receive active drug and to further evaluate the  safety of ruxolitinib 
cream 1.5% BID treatment.  
 
 
 
 
 
 
 
 
 
  
 
 
 
2.2.2.  Justification for Dose  
The dose that will be investigated in the current study is ruxolitinib cream 1.5% BID.  This is the 
dose that was selected for evaluation in the Phase 3 vitiligo studies based on findings from the 
completed Phase 2 study (INCB  18424 -211) conducted in adults with vitiligo, which evaluated 
4 dose strengths of ruxolitinib cream (1.5% BID, 1.5% QD, 0.5% QD, and 0.15%  QD).  The 
safety and efficacy outcomes from the Phase 2 study can be summarized as follows:  
• All ruxolitinib cream treatment  arms (1.5% BID, 1.5% QD, 0.5% QD, and 
0.15%  QD) demonstrated efficacy and superiority over vehicle in F -VASI50 and 
F-VASI75 at Week 24 , with a clear separation from vehicle emerging by Week 12.  
• At Week 24, 1.5% QD and BID treatment regimens further separa ted from the 0.15% 
and 0.5% treatment regimens , with the highest response at Week 24 in F -VASI50 
(50.0%) in the 1.5% QD regimen.  

Incyte Corporation   Page 20 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • The 1.5% BID treatment regimen demonstrated the highest response for F -VASI75 at 
both Week 24 (30.3%) and Week 52 (51.5%).  The T-VASI50 response in the 1.5% 
BID regimen was modest at Week 24 (12.1%); however, this regimen also 
demonstrated the highest response for T -VASI50 (36.4%) at Week 52, and it is 
recognized that repigmentation on nonfacial areas proceeds slower than on faci al 
areas.  
• All ruxolitinib treatment arms were generally safe and well -tolerated with no 
significant TEAEs or application site events and no clinically relevant hematologic 
changes through Week 52.  
Based on the above data, the treatment regimen of ruxolitin ib cream 1.5% BID was chosen for 
the current Phase  2 MOA  study.  
2.3. Benefit/Risk Assessment  
In nonclinical studies, ruxolitinib cream did not act as a contact sensitizer  and did not produce 
significant dermal irritation or demonstrate phototoxicity or photoallergic potential.  The lack of 
adverse cutaneous effects has been supported by clinical studies to date, where cutaneous AEs 
have been infrequent and of similar frequency and sev erity as with vehicle control treatment.  
Long -term immune suppression may occur with JAK inhibition, which could potentially increase 
the risk of cutaneous viral skin infections and nonmelanoma skin cancers.  Participants should be 
monitored  accordingly.  
The primary clinical risks noted with orally administered ruxolitinib for the treatment of 
polycythemia vera or myelofibrosis are the potential sequelae of decreased hematopoietic 
proliferation secondary to the inhibition of growth factor pathways by JAK2 antagonism.  
Dose -dependent, reversible thrombocytopenia has been observed in participants with 
myelofibrosis, as well as anemia and less frequently neutropenia.  An increased rate of infection 
is an additional potential risk of immunomodulation.  In healt hy participants and participants 
with rheumatoid arthritis with greater bone marrow reserve, the effects on hematopoietic 
proliferation appear to be less pronounced.  Owing to its low systemic bioavailability, topical 
ruxolitinib cream is not expected to b ring about clinically significant changes in hematology 
laboratory investigations.  
Results from the Phase 2 study (INCB  18424 -211) conducted in adults with vitiligo have been 
reported ( Rosmarin  et al 2020 ), and key f indings from this study are summarized in 
Section  2.2.1 .  Based on the Week 24 and Week 52 results, all active treatment groups were 
found to have no clinically relevant AEs related to the treatment regimens and were 
well-tolerated on application sites.  Safety findings from this study  were also unremarkable for 
laboratory values, vital signs, or physical examinations.  While minor changes in select 
hematology parameters (red blood cells and platelet counts) were noted in the laboratory 
assessments, they were mostly within the limits of the normal range of values, transient, 
asymptomatic, and clinically insignificant and did not necessitate any remedi al action.  
Currently, there are no approved therapies for vitiligo, and treatments are empirical and directed 
by the available clinical guidelines.  Current therapies often do not lead to satisfactory response, 
and there are limitations and safety concerns  with long -term use of some therapies, including 
Incyte Corporation   Page 21 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  topical or oral corticosteroids and calcineurin inhibitors.  Given the psychosocial burden and 
stigma that has been reported in this disease, patients with vitiligo warrant access to new studies.  
In summary,  ruxolitinib cream 1.5% BID can be safely used as a topical medication for vitiligo 
and represents the treatment regimen with the best benefit -to-risk ratio from among those 
investigated.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of ruxolitinib cream may be found in the IB. 
3. OBJECTIVES AND ENDPO INTS  
Table  5 presents the objectives and endpoints.  
Table  5: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the change in immune biomarkers 
in part icipants with vitiligo . • Percentage change from baseline in immune 
biomarkers , including CXCL10 , at Week  4, 
Week  12, and Week 24.  
Secondary  
• To correlate  the change in key  serum and  skin 
biomarkers of vitiligo to efficacy . • Correlation of  key skin inflammatory biomarkers 
of vitiligo in target  lesions to efficacy  readouts at 
Week  12 and  Week  24. 
• To assess the safety and local tolerability of 
ruxolitinib cream.  • The frequency and severity of AEs.  

Incyte Corporation   Page 22 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  4. STUDY DESIGN  
4.1. Overall Design  
This is a randomized, double -blind, vehicle -controlled study  with an open -label treatment 
extension period  in adult participants (age ≥  18 years) with nonsegmental vitiligo who have  
depigmented area s including ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on  nonfacial 
areas, and ≥ 3 T -VASI .  Total body involved vitiligo area (facial and nonfacial) should not 
exceed 50% BSA.  Approximately 60  participants will be randomized 2:1 to rec eive initial 
double -blind study treatment (ruxolitinib cream 1.5%:vehicle  BID) administered BID  for 
24 weeks (see  Figure  1).  Participants will be stratified by age (≤  40 years old and >  40 years 
old).   
During the double -blind treatment period, participants will receive ruxolitinib cream 1.5% BID 
or vehicle  BID for 24 weeks to be applied to depigmented areas on the face and bo dy up to 20% 
T-BSA.  For participants with depigmentation on >  20% BSA, the investigator will discuss with 
the participant which areas of vitiligo to treat and will document the areas to be treated in the 
eCRF.  Only those areas  identified for treatment at  baseline should be treated during the 
double -blind period; p articipants should continue to treat depigmented areas identified for 
treatment at baseline even if the area begins to improve or fully repigm ent.  Refer to Section  6.1 
for full information on study drug administration  and to Section  6.5 for information on dose 
modification and additional application guidance.  
After completion of the Week 24 assessments  from the double -blind treatment period , eligible 
participants will be offe red the opportunity to  continue  the study  in the 28 -week open -label 
treatment extension  period .  Participants initially randomized to vehicle will be crossed over to 
active drug (ruxolitinib cream 1.5% BID), and participants initially randomized to ruxolit inib 
cream will continue to receive treatment with ruxolitinib cream 1.5% BID.   To be eligible for the 
open -label treatment  extension period , participants must have completed the baseline and 
Week  24 visit assessments, be compliant with study procedures, a nd not have any safety issues.  
During the open -label treatment extension period, participants should continue to treat 
depigmented areas identified for treatment at baseline even if the area begin s to improve or fully 
repigment; additionally, if any new a reas of vitiligo have appeared since baseline, the new areas 
can be treated during the open -label treatment extension period .  The total treated area in the 
open -label treatment extension period  should not exceed 20% BSA ( facial and nonfacial).  
Safety endpoints, such as nature of AEs (type, frequency, and severity), vital signs, targeted 
physical examination, and routine laboratory investigations, will be monitored and recorded 
throughout the course of this study.    
  Samples for translational assessments (s erum, PBMCs, and skin biopsies ) will be 
collected from participants during the  study .  Following the last application of ruxolitinib cream 
at Week 52, there will be a 30 -day safety f ollow -up period . 
4.2. Overall Study Duration  
Screening is up to 42 days (~ 6 weeks); the double -blind, vehicle -controlled treatment period is 
24 weeks; the open -label  treatment extension  period is 28 we eks; and safety follow -up is 
30 days.  Total du ration is up to appr oximately 63  weeks (see  Figure  1). 

Incyte Corporation   Page 23 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  The study will b egin when the first participant  (or legally authorized representative ) signs the 
study ICF.  The end of the study is defined as the date of the last visit of the last participant in the 
study or the date that the last participant discontinued study drug and completed applicable safety 
follow -up assessments or is lost to follow -up. 
A participant is considered to have completed the study if he/she has completed all study visits, 
including the safety follow -up visit.  A study is considered completed when the last participant 
last visit has occurred.  
4.3. Study Termination  
The investigator r etains the right to terminate study participation at any time, according to the 
terms specified in the study contract.  The investigator is to notify the IRB/IEC of the study 's 
completion or early termination in writing, send a copy of the notification to the sponsor or 
sponsor 's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively or if required by regulatory agency.  In the event 
of significant safety findings, the study will be terminated.  If the  study is terminated 
prematurely, the sponsor or designee will notify the investigators, the IRBs/IECs, and regulatory 
bodies of the decision and reason for termination of the study.  
5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant  safety .  Therefore, 
adherence to the criteria as specified in the Protocol is e ssential .  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the foll owing criteria apply:  
1. Age ≥ 18 years.  
2. A clinical diagnosis of nonsegmental vitiligo with depigmented area s including ≥ 0.5% 
BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on n onfacial areas, and ≥ 3 T -VASI ; total 
body vitiligo area (facial and nonfacial) should not exceed 50% BSA.  
3. At least 1 active vitiligo lesion (eg, such as confetti lesion, trichrome appearance, pinkish 
rim, or other evidence of inflammatory activity ) at the site for skin biopsy.  
4. Agree to discontinue all agents used to treat vitiligo from scr eening through the final 
safety follow -up visit.  Over -the-counter preparations deemed acceptable by the 
investigator and camouflage makeups are permitted.  
Incyte Corporation   Page 24 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  5. Willing ness to take appropriate contraceptive measures to avoid pregnancy or fathering a 
child for t he duration of study participation with the exception of the following:  
a. Female  participant s of non childbearing potential (ie, surgically sterile with a 
hysterectomy and/or bilateral  oophorectomy OR postmenopausal [ ≥ 12 months of 
amenorrhea without an alter native medical cause ]). 
Note:  Information about specific types of acceptable contraceptive measures and 
duration of contraceptive use are provided in  Appendix  A. 
6. Ability to comprehend and willingness to sign an IC F. 
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. No pigmented hair within any of the vitiligo areas on the face.  
2. Other forms of vitiligo  (eg, segmental) or other differential diagnosis of vitiligo or other 
skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory 
hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical 
leukoderma, and tin ea versicolor).  
3. Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other 
pigmented areas.  
Note:  Prior use of hydroquinone is not prohibited ( because  it is a bleaching agent, not a 
depigmentation treatment).  
4. Concurrent conditions and history of other diseases:  
a. Any other skin disease that, in the opinion of the investigator, would interfere with 
the study medication application or study assessments.  
b. Active acute bacterial, fungal, or viral skin infection (eg, herpes simpl ex, herpes 
zoster, chickenpox) within 1 week before baseline.  
c. Conditions at baseline that would interfere with evaluation of vitiligo.  
d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator 's opinion, would interfer e with full participation in the study, including 
administration of study drug and attending required study visits; pose a significant 
risk to the participant; or interfere with interp retation of study data.  Examples include 
but are not limited to the following:  
− Clinically significant or uncontrolled cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from Day 1 of study drug 
administration, New York Heart Association Class III or IV congestive heart 
failure, and arrh ythmia requiring therapy or uncontrolled hypertension (blood 
pressure > 150/90 mmHg) unless approved by the medical monitor/sponsor.  
− History of thrombosis, including deep venous thrombosis and pulmonary 
embolism.  
− Concurrent malignant diseas e or a history o f that in the 5  years preceding the 
baseline visit except for adequately treated nonmetastatic malignancies.  
Incyte Corporation   Page 25 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  − Current and/or history of liver disease, including known hepatitis B or C, with 
hepatic or biliary abnormalities.  
− Current and/or history of tubercu losis.  
− History of alcohol  use disorder or drug addiction within 1 year before screening 
or current alcohol or drug use that, in the opinion of the investigator, will interfere 
with the participant 's ability to comply with the administration schedule and st udy 
assessments.  
− Committed to an institution by virtue of an order issued either by the judicial or 
the administrative authorities.  
5. Use of  any of the following treatments within the indicated washout period before 
baseline:  
a. 1 week:   Topical drugs when used  on the vitiligo areas, for example, corticosteroids, 
calcineurin, and phosphodiesterase type 4 inhibitors or retinoids.  
b. 4 weeks:  
− Melanocyte -stimulating agents (eg, afamelanotide).  
− Immunomodulating systemic medications (eg, corticosteroids, methotrexate, 
cyclosporine).  
− Any other systemic therapies that could increase the skin sensitivity to UV/visible 
light or impact skin pigmentation, for example, tetracyclines, met hoxypsoralens.  
− Received live vaccine.  
Note:  Live vaccine is prohibited during the course of  the study and within 
4 weeks after the EOT visit.  
c. 8 weeks:   Laser or any kind of phototherapy, including tanning bed s or intentional 
UV exposure.  
d. 5 half -lives  or 12 weeks , whichever is longer:  biologic agents, investigational or 
experimental therapy , or procedures for vitiligo.  Investigational biologics should be 
discussed with the sponsor to determine whether a longer period of discontinuation is 
required.  
6. Previously received JAK inhibitors, systemic or topical.  
7. Investigator -determined clinically si gnificant abnormal laboratory values at screening:  
a. Hemoglobin (< 10 g/dL).  
b. Liver function tests:  
− AST or ALT ≥ 2 × ULN.  
− Alkaline phosphatase and/or bilirubin > 1.5 × ULN (isolated bilirubin 
> 1.5 × ULN is acceptable if bilirubin is fractionated and direc t bilirubin < 35%).  
c. Severe renal disease (with creatinine clearance <  30 mL/min) or renal disease 
requiring dialysis.  
Incyte Corporation   Page 26 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  d. Clinically significant abnormal TSH or free T4 at screening as determined by the 
investigator.  
e. Positive serology test results at screening  for HIV antibody.  
f. Hepatitis B  virus  or HCV infection:  Participants who are positive for hepatitis B 
surface antigen or hepatitis B core antibody will be eligible if they are negative for 
HBV DNA; these participants should be considered for prophylactic a ntiviral therapy.  
Participants who are positive for anti -HCV antibody will be eligible if they are 
negative for HCV -RNA.  
8. Body mass index < 17 or > 40 kg/m2. 
9. Pregnant or lactating, or considering pregnancy during the period of their study 
participation.  
10. In the opinion of the investigator are unable or unlikely to comply with the administration 
schedule and study evaluations.  
11. Employees of the sponsor or investigator or are otherwise dependents of them.  
12. Known allergy or reaction to any component of the study  formulation.  
13. Live with anyone participating in any current Incyte -sponsored ruxolitinib cream study.  
5.3. Lifestyle Considerations  
Participants should be cautioned to avoid excessive exposure to artificial sunlight (including 
tanning beds, sun lamps, etc).  
If sunscreen, makeup, or other cosmetics have been applied to the areas to be treated, participants 
should follow the application guidance (see Section  6.6.1 ). 
It is recommended that swimming should not take place within 2 hours before and after the 
planned study drug application.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subse quently randomly assigned to study treatment.  Tests with results that fail eligibility 
requirements may be repeated once during screening if the investigator believes  that the 
participant would be eligible if retested.  Additionally, a participant who fai ls screening may 
repeat the screening process 1 time if the investigator believes that there has been a change in 
eligibility status or any laboratory abnormality is inconsistent with the participant 's medical 
history.  Participants who rescreen must  recon sent and  be assigned a new screening number.  
5.5. Replacement of Participants  
No participants will be replaced at any time during this study.  
Incyte Corporation   Page 27 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  6. STUDY TREATMENT  
See Appendix  C for COVID -19–related guidance.  
6.1. Study Treatments  Administered  
Table  6 presents the study treatment information.  
Table  6: Study Treatment Information  
 Ruxolitinib  Vehicle  
Study treatment name:    
MOA : Inhibitor of the JAK family of 
protein tyrosine kinases  Not applicable  
Dosage formulation:  Cream  
Unit dose strength(s)/dosage 
level(s):  1.5%  Not applicable  
Route of administration:  Topical  
Administration 
instructions:  A thin film is applied BID to depigmented vitiligo areas  on the face 
and body  up to  20% T-BSA . 
Packaging and labeling:  Ruxolitinib cream and vehicle cream will be provided in 60 g tube s.  
Each tube will be labeled as required per country requirement.  
Storage:  Ambient (15°C -30°C/59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  Not applicable  
The application of study drug will be limited to ≤ 20% of the participant 's T-BSA , regardless of 
whether the participant has depigmentation on >  20% BSA .  For participants with 
depigmentation on >  20% BSA, the investigator will discuss with the participant at baseline 
(Day  1) which areas of vi tiligo to treat, and the areas  selected for treatment must include all areas 
in which skin biopsies will be performed.  The site should document the area to be treated in the 
eCRF.  
All tubes of study drug will be weighed before being di spensed.  All returned tubes of study drug 
will also be weighed.  
Study drug will be applied as a thin film BID, with applications at least 8 hours apart.   
Participants should remove study drug from the tube in fingertip units until all of the areas to be 
treated are covered by a thin film.  
Participants will be instructed to document treated areas and advised to l imit use to no more than 
1 tube  (60 g) per 3-4 days .  Application instructions will be provided by the site study staff, and 
the participants will record their daily applications via a diary card given to the participants 
during each study visit.  Refer to the Study Pharmacy Manual for participant instructions for 
handling of study drug.  
Incyte Corporation   Page 28 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  On the day of a visit,  the participant should not apply the ir morning dose of  study drug at home ; 
instead, s tudy drug will be applied  from a new kit in the clinic during the  visit, under direc t 
supervision of the site staff .  The tube will be weighed before and after  application to determine 
the participant 's dosage . 
At any time  during the study , if vitiligo areas become significantly more extensive than from the 
previous visit, the participant should contact the study site to discuss with the investigator 
whether additional evaluation at the clinic is required.  If any other skin products that are 
permitted under the study Protocol are used, participants should continue th ese unchanged during 
the study.  
6.1.1.  Application During the Double -Blind, Vehicle -Controlled Treatment Period  
During the double -blind, vehicle -controlled treatment period  (up to Week 24 ), participants 
should follow the s tudy drug application guidance  below : 
• Participants should apply study drug only to depigmented vitiligo areas  identified by 
the investigators at baseline  (Day 1)  up to a T -BSA (facial and no nfacial) of  ≤ 20%.  
• Participants should continue to treat all depigmented vitiligo areas identified for 
treatment at baseline even if the area begins  to improve or fully repigment.  
• Participants who have an expansion of existing areas of vitiligo during the course of 
the double -blind  period may treat these areas after a visit to document the VASI and 
other measures of vitiligo (may be an unscheduled visit), as long as the new treated 
T-BSA (facial and nonfacial) does not exceed 20% BSA.  
• Participants who develop new vitiligo lesions during the course of the double -blind 
period should not treat these areas during the double -blind  period.   Newly developing 
vitiligo lesions should be documented in the eCRF, and the VASI for these new 
lesions should not be calculated and combined together with the area(s) to be treated 
identified at baseline . 
6.1.2.  Application During the Open -Label Treatment Exten sion Period  
During the open -label treatment extension period  (after Week 24) , participants should follow the 
study drug application guidance  below : 
• Participants should apply study drug to depigmented vitiligo areas  identified by the 
investigators at baseli ne (Day 1) up to a T -BSA (facial and nonfacial) of  ≤ 20%.  
• Participants should continue to treat all depigmented vitiligo areas identified for 
treatment at baseline even if the area begins to improve or fully repigment.  
• Participants who have a n expansion of  existing areas of vitiligo during the course of 
the open -label period may treat these areas after a visit to document the VASI and 
other measures of vitiligo (may be an unscheduled visit), as long as the new treated 
T-BSA (facial and nonfa cial) does not e xceed 20% BSA.  
Incyte Corporation   Page 29 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • Participants who develop new vitiligo lesions during the course of study  may treat 
these areas  during the open -label period  after a visit to document the VASI and other 
measures of vitiligo (may be an unscheduled visit ), as long as the new treated T -BSA 
(facial and nonfacial) does not exceed 20% BSA.  Newly developing vitiligo lesions 
should be documented in the eCRF and the VASI for these new lesions should not be 
calculated and combined together with the area(s) to be treated identified at  baseline.  
6.2. Preparation , Handling , and Accountability  
The investigator or designee must confirm and document that  appropriate temperature conditions 
(both ruxolitinib cream and vehicle cream are to be stored between 15°C and 30°C [59°F -86°F]) 
have been mai ntained during transit for all study drugs  received and any discrepancies are 
reported and resolved before use of the study drug. 
Only participants enrolled in the study may receive study drug, and only authorized site staff 
may supply study drug.  Immedia tely after application of study drug , participants are to wash 
their hands thoroughly with soap and warm water  (unless the area to be treated includes the 
hands) .  Refer to the Study Pharmacy Manual for participant instructions for handling of study 
drug.  
All study drug must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions , with access limited to the 
investigator and authorized site staff.  Participants should store  study drug at ambient 
temperature conditions.  
The investigator  (or designee)  is responsible for study treatment  accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records) .  Inventory and 
accountabil ity records must be maintained and readily available for inspection by the study 
monitor and are open to inspection at any time by any applicable regulatory authorities .  The 
investigator (or designee ) must maintain records that document:  
• Delivery of study  drugs to the study site.  
• Inventory of study drug s at the site.  
• Participant use of the study drug s, including tube counts from each supply dispensed.  
• Return of study drug s to the investigator or designee by participants.  
The investigational product  must be used only in accordance with the Protocol .  The investigator 
will also maintain records adequately documenting that the participants were provided the 
specified study drug .  These records should include dates, quantities, and any available batch o r 
serial numbers or unique code numbers assigned to the investigational product  and study 
participants.  
Completed accountability records will be archived by the site .  The investigator  or designee will 
be expected to collect and retain all used, unused, an d partially used containers of study drug 
until verified by the study monitor (unless otherwise agreed to by the sponsor) .  At the 
conclusion  of the study, the investigator or designee will oversee shipment of any remaining 
study drug back to the sponsor o r its designee for destruction according to institutional SOPs .  If 
local procedures mandate on -site destruction of the investigational supply, the site should (where 
Incyte Corporation   Page 30 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  local procedures allow) maintain the investigational supply until the study monitor inspe cts the 
accountability records in order to evaluate compliance and accuracy of accountability by the 
investigative site .  At sites where the study drug is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site S OP. 
Further guidance and information for the final disposition of unused study drugs  is included  in 
the study materials provided to sites . 
6.3. Measures to Minimize Bias:  Randomization and Blinding  
All participants will be centrally assigned to study treatment using an IRT system.  The system 
will assign study treatment in a 2:1 ratio ( ruxolitinib cream 1.5% BID:vehicle  BID), stratified by 
age (≤  40 years old and >  40 years old) .  The IRT will assign participant ID numbers, track 
participant visits, randomize participants according to the defined parameters,  maintain the 
blinding, and manage study drug inventory.  Full details will be provided in the IRT Manual.  
Study treatment will be dispensed at the study visits summarized in the SoA (see Table  3 and 
Table  4). 
After the database lock for the pr imary analysis, the sponsor will be unblinded, but investigators 
and participants will still be blinded to individual  treatment assignment s.  This is implemented to 
minimize bias for the Week 52 an alyses .  After Week 52, investigators and participants will  be 
unblinded.  
6.4. Study Treatment Compliance  
Compliance with all study -related treatments must be emphasized to the participant by the site 
personnel, and appropriate steps should be taken to optimize compliance during the study.  
Compliance with ruxolitinib cream  or vehicle  will be evaluated by participants ' adherence to the 
application regimen and drug accountability documented by the site staff and monitored by the 
sponsor/designee (tube count s). 
In general, the application compliance will be determined by the number of actual versus 
anticipated number of applications, which should be at least 70% but no more than 130%  of the 
prescribed number of applications.  Participants will be ins tructed to br ing all study drug  with 
them to the study visits in order for site personnel to conduct tube counts to assess study drug 
accountability.  The drug accountability documentation will be used by the sponsor to calculate 
treatment compliance.  
6.5. Dose Modifica tions 
6.5.1.  Criteria and Procedures for Dose Interruptions and Adjustments of Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine if the participant should continue or discontinue study treatment.  
In some circumstances, it may be necessary to temporarily interrupt treatment with study drug .  
Except in cases of emergency, it is recommended that any findings of concern (eg, AE) be 
confirmed and that the investigator consult with the sponsor 's medical mon itor (or other 
representative of the sponsor) before interrupting study drug.  Additionally, the investigator must 
obtain approval from the sponsor before restarting study drug.  Participants who experience a 
Incyte Corporation   Page 31 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  recurrence of the initial AEs upon restarting t he study drug may need the study drug to be 
permanently discontinued.  
Instructions for application interruptions of study drug  are outlined in Table 7.  Indivi dual 
decisions regarding interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the study 
treatment and the participant 's underlying condition.  
Table 7: Guidelines for Interruption and Restarting of Study Drug  
Adverse Event  Action Taken  
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Study drug applications must be interrupted.  At the 
discretion of the investigator, after consultation with 
the sponsor, study drug application may be restored 
once these have resolved.  
Other laboratory abnormalities  
Any other Grade 3 laboratory abnormality, 
with the exception of asymptomatic 
elevations in triglyceride, cholesterol, or 
amylase  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Study drug applications must be interrupted.  At the 
discretion of the investigator, after consultation with 
the sponsor, study drug application may be restored 
once these have resolved.  
Any Grade 4 laboratory abnormality or 
AST or ALT (> 5 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Discontinue study drug if lab oratory  abnormalities are 
confirmed.  
6.5.2.  Criteria for Permanent Discontinuation of Study Drug  
The occurrence of unacceptable severity of an AE not caused by the underlying disease will be 
presumed to be related to study drug and will require that the study drug be permanently 
discontinued.  Unacceptable severity is defined as follows:  
• Occurrence of an AE that is related to treatment with the study drug that, in the 
judgment of the investigator or the sponsor 's medical monitor, compromises the 
participant 's ability to continue study -specific procedures or continuing treatment is 
considered to not be in the participant 's best interest.  
• Worsening of vitiligo that requires treatment with a prohibited concomitant 
medication.  
See Section  7 for discontinuation procedures.  
Incyte Corporation   Page 32 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  6.6. Concomitant Medications  and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, an d/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to 4 2 days before the first dose of study drug through 30 days after 
the last dose of study drug will be recorded in the eCRF.  Any addition, deletion, or change in th e 
dose of these medications will also be recorde d.  Concomitant medications administered after 
30 days after the last dose of study drug should be recorded in the eCRF only if the medication 
was administered due to an SAE (as defined in Section  9.2).  Con comitant treatments/procedures 
that are required to manage a participant 's medical condition during the study will also be 
recorded in the eCRF.  The medical monitor should be contacted if there are any questions 
regarding concomitant or prior therapy.  
6.6.1.  Permitted Medications  and Procedures  
The following are permitted during the study with application guidance.  Investigators and site 
staff are expected t o use their best clinical judgment with these recommendations and adhere to 
the guidelines as closely as possible.  Please consult the sponsor if there are specific questions.  
• Participants may use bland emollients or camouflage makeups.  
Note:  Emollients o r camouflage makeups should not be used within 2 hours after 
study drug application.  The study drug may not be applied over sunscreens and 
camouflage makeup.  These must be carefully removed from the skin before 
application of the study drug.  Any makeup remover must then be washed off and the 
skin dried before application of the study drug.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide – or titanium 
oxide –based) with SPF of at least 30 may be used at least 2  hours after study drug 
application.  
Note:  Sunscreen must be carefully removed from the skin before study drug 
application if it has been applied to the areas to be treated.  
• Study drug should be applied at least 2 hours after shaving.  
• Concomitant oral vitamins and other skin pro ducts should be approved by the 
investigator and ideally should remain stable during the study.  
6.6.2.  Restricted Medications  and Procedures  
The following are restricted during the study under specified conditions:  
• Use of any over -the-counter, nonprescription pre parations (including vitamins, 
minerals, and phytotherapeutic, herbal, or plant -derived preparations) within 7 days 
before the baseline visit through the safety follow -up visit, unless deemed acceptable 
by the investigator.  
• Use of any prescription medicati on (including immunizations, phytotherapeutic, 
herbal, or plant -derived preparations) within 7 days before the baseline visit through 
the safety follow -up visit, unless deemed acceptable by the investigator.  
Incyte Corporation   Page 33 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • Baths or showers within 2 hours after study drug  application.  
• Treatment for dermatologic disease besides vitiligo (eg, atopic dermatitis  or psoriasis) 
is allowed for areas not being treated for vitiligo , if: 
− It involves  < 10% of the BSA outside of the areas treated for vitiligo.  
− Topical tacrolimus, pime crolimus, or corticosteroids Class 6 or 7 (or low potency 
per WHO classification; see  Appendix  B) are at a stable dose.  
− Topical corticosteroids Class 1 through 5 (see Appendix  B) are used for no longer 
than 7 sequential days and no more than 14 days in total.  
• Use of oral corticosteroids for no longer than 7 days if deemed acceptable by the 
investigator and the sponsor for nondermatologic conditions (eg, asthma 
exacerbation, bronchitis).  
6.6.3.  Prohibited Medications  and Procedures  
Participants should not use any other treatm ents for vitiligo at any time during the study.  The 
following medications are not permitted during the study:  
• Any investigational medication other than the study drug  
• Treatment known to affect the course of vitiligo, such as skin bleaching treatments 
(eg, hydroquinone) or depigmenting agents (eg, monobenzone)  
Note:  Skin bleaching (eg, hydroquinone) is prohibited during the study but is  allowed 
as prior therapy.  
• Other topical agents (except those in Section  6.6.1 ) or treatments for vitiligo 
(including corticosteroids [topical, systemic, or oral], vitamin D derivatives, 
calcineurin inhibitors, laser or surgical treatments, phototherapy, or other procedu res) 
• Biologic therapies or other immunosuppressant agents  
• Any phototherapy, including tanning beds  
• Live or live -attenuated vaccination  
6.7. Treatment After the End of the Study  
No treatment will be provided after the end of the study.  
Incyte Corporation   Page 34 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  7. DISCONTINUATION OF S TUDY TREATMENT  AND 
PARTICIPANT WITHDRAW AL 
7.1. Discontinuation of Study Treatment  
7.1.1.  Reasons for Discontinuation  
Participants must  be discontinued from study treatment for the following reasons:  
• A participant is found not to have met eligibility criteria (any exclusion criterion or 
any inclusion criteri on related to participant safety) or if legal requirements have been 
violated.  
• The participant becomes pregnant.  
• Consent is withdrawn.  
Note:  Consent withdrawn means that the participant has explicitly indicated that 
he/she  does not want to be followed any longer; in this case no further data, except 
data in the public domain, may be solicited from or collected on the participant.  
Participants may choose to discontinue study treatment and remain in the study for 
safet y monitoring.  
• Further participation would be injurious to the participant 's health or well -being, in 
the investigator 's medical judgment.  
• Any AE of unacceptable severity as noted in Section  6.5.2 . 
• The study is terminated by the sponsor.  
• The study is terminated by the local health authority, IRB, or IEC.  
A participant  may be discontinued from study treatment as follows:  
• If, at 2 consecutive study visi ts, a participant 's drug usage e xceeds 1 tube ( 60 g) per 
3-4 days . 
• If a participant is noncompliant with study procedures or study drug administration in 
the investigator 's opinion, the medical monitor should be consulted for instruction on 
handling the pa rticipant.  
7.1.2.  Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment, an EOT 
visit should be conducted (EOT1 or EOT2 , depending on the period during with the participant 
discontinues treatment).  Reaso nable efforts should be made to have the participant return for a 
safety follow -up visit.  These visits are described in Table  3 and Table  4.  The last date of the last 
dose of study drug and the reason for discontinuation of study drug will be recorded in the eCRF.  
If a participant i s discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for discontinuation must be documented in the participant 's medical 
record and the primary reason for discontinuation must be included in the eCRF.  
Incyte Corporation   Page 35 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • An EOT vis it should be performed (EOT1 or EOT2 , depending on the period during 
with the participant discontinues treatment).  
• The date of the EOT visit should be recorded in the eCRF.  
• Participants must be followed for safety until the time of the safety follow -up vis it or 
until study treatment –related AEs resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data (safety follow -up or dise ase assessment), then no additional data collection 
should occur; however, participants will have the option of withdrawing consent for study 
treatment but continuing in the safety follow -up period of the study for safety  
assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons.  
If a participant wit hdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
See Table  3 and Table  4 for data to be collected at the time of study withdrawal and follow -up 
and f or any further evaluations that need to be completed.  
7.3. Lost to Follow -Up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions m ust be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible.  The site will counsel the participant on the importance of 
mainta ining the assigned visit schedule and will ascertain whether or not the 
participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant 's last known mailing address 
or local equivalent methods).  These contact attempts should be documented in the 
participant 's medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 

Incyte Corporation   Page 36 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8. STUDY ASSESSMENTS AN D PROCEDURES  
See Appendix  C for COVID -19–related guidance.  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study.  
− Informed consent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by the Protocol.  
− Informed consent must be obtained using the IRB/IEC -approved version  in a 
language that is native and understandable to the participant.  A template will be 
provided by the sponsor or its designee.  The sponsor or its designee must review 
and acknowledge the site -specific changes to the ICF template.  The ICF must 
include a statement that the sponsor or its designee and regulatory authorities have 
direct access to participant records.  
− The ICF must contain all required elements and describe the nature, scope, and 
possible consequences of the study in a form unde rstandable to the study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requiremen ts and regulations for the country in 
which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that his/her personal study -related data will be used 
by the sponsor in accordance with local data protection laws.  The level of disclosure 
must also be explained to the participant.  
• The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the 
sponsor, by approp riate IRB/IEC members, and by inspectors from regulatory 
authorities.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  Th e authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants must provide consent to the most current version of the ICF during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the par ticipant 's legally 
authorized representative.  
• Participants who are rescreened are required to sign a new ICF.  
Incyte Corporation   Page 37 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8.1.2.  Screening Procedures  
Screening is the interval between signing the ICF and the day that the participant is assigned to 
the study drug (Day  1).  Screening assessments for determination of eligibility may be performed 
over a period lasting up to 4 2 days.  
Procedures conducted as part of the participant 's routine clinical management (eg, clinical 
laboratory tests) and collected before informed consent  is obtained may be used for screening or 
baseline purposes, provided the procedure meets the Protocol -defined criteria and has been 
performed within 4 2 days before Day 1.  All information associated with eligibility 
requirements, including demography and medical history, must be entered into the appropriate 
eCRF pages.  
Results from the screening assessments will be reviewed by the investigators to confirm 
eligibility before Day 1 and administration of study drug.  Test results that fail eligibility 
require ments may be repeated once during screening if the investigator believes that the 
participant would be eligible if retested.  For screening assessments that are repeated, the most 
recently available result before administration of study drug will be used t o determine eligibility.  
See Section  5.4 regarding screen failures.  
8.1.3.  Interactive Response Technology Procedure  
Each participant will be identified in  the study by a participant ID number, which is a 
combination of the site ID and participant number.  Site personnel should contact the IRT system 
to obtain the participant ID number during screening.  Upon determining that the participant is 
eligible for study entry, the IRT system will be contacted to obtain the study treatment kit 
assignment.  Additionally, the IRT system will be contacted at each regular study visit to update 
the study drug supply.  Additional details are provided in the IRT Manual.  
8.1.4.  Distribution of Reminder Cards and Diaries  
Starting at the baseline ( Day 1 ) visit and each visit thereafter  (except for the Week 24 [EOT1],  
Week 52  [EOT 2], and EOS visits) , a study drug –specific diary will be given to each participant 
in order to record use of the study drug.  The completed diary will be collected during each of the 
participant 's visits.  
Qualified clinical site staff will review the participants ' entries for compliance.  Participants who 
are noncompliant with their study drug schedule (define d as < 70% or > 130% of the expected 
number of applications between study visits) will have their administration instructions 
reinforced by the investigator or a qualified designee.  Participants will be considered compliant 
with the treatment regimen if t hey apply at least 70% but no more than 130% of the expected 
applications during participation in the  treatment period of the study.  
Participants will be provided with a reminder card starting on Day 1 and at all visits (through 
Week 52).  The reminder car d will indicate the date/time of the next visit and will also remind 
the participant that on visit days, they will perform  their morning study drug application at the 
clinic during the visit under site supervision after their blood draws for  safety evaluations 
have been completed.  

Incyte Corporation   Page 38 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8.1.5.  Demography and Medical History  
8.1.5.1.  Demographics and General Medical History  
Demographic data and general medical history will be collected at screening by the investigator 
or qualified designee and will include year of birth/ag e, race, ethnicity, medical and surgical 
history, and current illnesses.  Medical history will include relevant medical or surgical treatment 
within the past 2 years that are considered to be clinically significant by the investigator.  
8.1.5.2.  Disease Characterist ics and Treatment History  
A vitiligo medical and treatment history, including date of diagnosis, relevant disease 
characteristics, and prior treatments, including systemic treatments, phototherapy, and surgical 
procedures, will be recorded.  A medical hist ory of other conditions related to vitiligo will also 
be collected at screening.  
  
  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

Incyte Corporation   Page 39 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3. Safety Assessments  
Planned timepoints for all safety assessments are provided in Table  3 and Table  4. 
See Section  6.5 for guidelines regarding the management of re levant laboratory or other safety 
assessment abnormalities.  
8.3.1.  Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF until at least 
30 days after the last dose of study drug.  Adverse events for randomized participants that begin 
or worsen after informed consent should be recorded on the Adverse Event Form in the eCRF 
regardless of the assumption of a causal relationship with the study drug.  Conditions that were 
already present at the time of informed consent should be recorded on the Medical History Form 
in the eCRF.  Adverse events (including laboratory abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible rather than by individual underlying signs and 
symptoms.  
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative).  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that me et 
the definition of an AE or SAE and remain responsible for following  up on AEs that are serious, 
considered related to the study drug, or that caused the participant to discontinue the study drug.  
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant, such as "How are you feeling? ", is the preferred 
method to inquire about AE occurrences.  Adverse events may also be detected when they are 
volunteered by the participant du ring the screening process or between visits or through physical 
examinations, laboratory tests, or other assessments.  The definition, reporting, and recording 
requirements for AEs are  described in Section  9. 

Incyte Corporation   Page 40 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  All SAEs will be reported to the sponsor or designee within 24 hours.  The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available.  
After the initial AE/S AE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
8.3.2.  Physical Examinations  
Physical examinations will be conducted at the timepoints listed in Table  3 and Table  4. 
A comprehensive physical examination will include height and body w eight and assessment of 
the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes.  A brief 
neurologic examination will also be performed.  
A targeted physical examination should be conducted as indicated by symptoms reported by the 
partic ipant, AEs, or other findings.  
Physical examinations must be performed by a medically qualified individual such as a licensed 
physic ian, a physician assistant,  or an advanced registered nurse practitioner, as local law 
permits.   Abnormalities identified after the first dose of study drug constitute an AE if they are 
considered clinically meaningful, induce clinical signs or symptoms, require concomitant 
therapy,  or require changes in study treatment.  
8.3.3.  Vital Signs  
Vital sign measurements will be taken  at all visits . 
Vital sign measurements  include blood pressure, pulse, respiratory rate, and body temperature.  
Blood pressure and pulse will be taken with the participant in the recumbent, semirecumbent, or 
sitting position after 5 minutes of rest.  Any abnormalities that are considered clinically 
significant in the judgment of the investigator are to be reported as AEs.  
8.3.4.  Electrocardiograms  
Electrocardiograms will be performed as indicated in Table  3. 
All 12 -lead ECGs will be performed with the participant in a recumbent or semirecumbent 
position after 5 minutes of rest.  Additional 12 -lead ECGs may be performed at other visits as 
deemed  clinically necessary.  Findings from a 12 -lead ECG performed within 2 months before 
baseline are acceptable to use  as the participant 's screening value.  
ECGs  will be inter preted by the investigator at the site or designee, and the results will be used 
for immediate management of the participant 's care.  There is no central reader of ECGs for this 
study.  The decision to include or exclude a participant or withdraw a partici pant from the study 
based on an ECG flagged as "Abnormal, Clinically Significant " is the responsibility of the 
investigator, in consultation with the sponsor 's medical monitor, as appropriate.  Any 
abnormalities that are considered clinically significant i n the judgment of the investigator are to 
be reported as AEs.  
Incyte Corporation   Page 41 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8.3.5.  Laboratory Assessments  
Required clinical laboratory tests are listed in Table  8, which include h ematology, chemistry, 
urinalysis, serology, free T4, TSH, FSH, and pregnancy test ing, and will be performed as 
indicated in Table  3 and Table  4.  Clinical laboratory tests will be performed at a central 
laboratory (refer to the Laboratory Manual for sample handling and shipping instructi ons).  
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by the investigator to be more severe than expected for the 
participant 's condition.  All laboratory tests with values co nsidered clinically significantly 
abnormal during participation in the study, or within 30 days after the last dose of study drug, 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically significant by the in vestigator or medical monitor.  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Table  8: Required Laboratory Analytes  
Serum Chemistriesa Hematology  Urinalysis With 
Microscopic 
Examination  Serology  Other  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Bicarbonate or CO 2 
Blood urea nitrogen or 
urea 
Calcium  
Chloride  
Creatinine  
Glucose  
Lactate dehydrogenase  
Phosphate  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin (if total 
bilirubin is elevated 
above ULN)  
Total protein  Complete blood 
count, including:  
• Hemoglobin  
• Hematocrit  
• Mean 
corpuscular 
volume (MCV)  
• Platelet count  
• Mean platelet 
volume  
• Red blood cell 
count  
• Reticulocyte 
count  
• White blood cell 
count  
 
Differential count, 
including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  Color and 
appearance  
pH and specific 
gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  Hepatitis B surface 
antigen  
Hepatitis B core 
antibody  
Hepatitis B core 
immunoglobulin M 
antibody  
HCV  antibody  
HCV -RNA (only 
performed if 
antibody positive)  
HIV antibody  FSHb 
Free T4  
TSH  
Pregnancy Testing  
Female participants of childbearing potential will undergo  a 
serum test at the screening and safety follow -up visits.  A urine 
test will be conducted at all other visits.  A positive urine test 
will be confirmed by a serum test.  
Note:  Additional tests may be required, as agreed upon by the investigator and sponsor, based on emerging safety data  or to rule 
out a diagnosis . 
a All serum chemistries will be performed on samples collected without respect to food intake (ie, nonfasting).  
b FSH is only measured  for postmenopausal women (defined by amenorrhea for ≥ 12 months without an alternative medical 
cause before screening); FSH should be in the postmenopausal range to consider the participant of nonchildbearing potential.  
Incyte Corporation   Page 42 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  8.3.5.1.  Pregnancy Testing  
A serum pregnancy  test will be required for all women of childbearing potential during screening 
and at the safety follow -up visit (30 [+ 7] days after EOT; EOT1 or EOT2 as applicable).  Urine 
pregnancy tests will be conducted as outlined in Table  3 and Table  4, as medically indicated, or 
per country -specific requireme nt.  Urine pregnancy tests will be performed locally.  If a urine 
pregnancy test is positive, the result should be confirmed with a serum pregnancy test, which 
may be performed locally.  
If the serum pregnancy test is negative after a urine test was positiv e, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant 's best 
interest to resume study drug and continue participation in the study.  
If a pregnancy is confirmed by a serum pregnancy test , see Section  9.7 for reporting 
requirements.  
8.3.5.2.  Serology  
Hepatitis and HIV screening assessments will be performed during the  screening period  to rule 
out infection; required analytes are shown in Table  8. 
Serology tests should be performed early in the screening process due to the length of time 
needed to obtain the results.  Additional tests may be performed if clinically indicated.  
8.5. Pharmacodynamic and Translational Assessments  
All participants will have serum ,  and 2.5-mm skin biopsies collected at the visits  
outlined in  Table  3.  Serum  will be used for changes in immune parameters, 
including but not limited to soluble proteins, such as cytokine s and  chemokines,   
.   

Incyte Corporation   Page 43 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL   
 
All analys es will be conducted by Incyte Corporation (Wilmington, DE) or Incyte 's designee.  
Refer to the procedure -specific Study Manuals for detailed instructions.  
8.5.1.  Skin Biopsy  
Skin biopsies  (2.5 mm punch biopsy) will be collected from a target lesion at the timepoints 
outlined in  Table  3.  Skin biopsies can not be taken from the  hands , feet, head/neck, face , and 
genital area .  The target lesion for skin bio psy should be defined at baseline (Day 1)  as an active 
vitiligo lesion, such as confetti lesion, trichrome appearance, pinkish rim , or other evidence of 
inflammatory activity and/or active ch anges to the lesion .  
 small (2.5  mm, which does not requir e stitches) biopsies will be collected from lesional skin 
at each timepoint  (Baseline/ Day 1 , Week 12, Week 24, and Week 40)  
.  At baseline  (Day 1) , an additional   small (2.5  mm) skin biopsies will also be collected 
from  nonlesional skin  adjacent to the target  lesion , .   
small biopsies will be taken at each timepoint to accommodate different analyses, each requiring 
profoundly different processing.  At each timepoint, 1 biopsy will  be processed for 
immunohistochemistry and other imaging technologies to enable protein and gene expression 
analyses by imaging,  
    
The skin biopsi es at Week 12, Week 24 , and Week 4 0 will be collected in the vicinity but at least 
1 cm distant  from where the biopsies were collected at baseline ( Day 1 ), even if the target lesion  
area has cleared.   The b aseline (Day 1) lesional s kin biopsy sampling area  should be from the 
inside edge of a n active  vitiligo lesion, and the sampling area should be entirely contained within 
lesional skin.  
Details about the collection, processing, handling, storage , and shipping of sam ples will be 
provided in the Study Manua ls. 
 
 
 
 
 
 
 
 
 

Incyte Corporation   Page 44 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898 CONFIDENTIAL  8.5.3.  Immunohistology and Other Imaging Techniques  
Analyses will be performed  to evaluate skin  
 biomarkers.   This will enable , but not limit, the evaluation of changes in leukocyte 
infiltration to vitiligo lesions and the  correlat ion with biological response relating to  vitiligo or 
the MOA  of ruxolitinib 1.5% cream.  
8.6. Unscheduled Visits  
Unscheduled visits may occur at any time at the investigator 's discretion, and appropriate clinical 
and laboratory tests may be performed, as clinically indicated.  
8.7. End of Treatment  and/or Early Termination  
If a decision is made that the participant will permanently discontinue study drug, then an EOT 
visit should be conducted (EOT1 or EOT2 , depending on the study period when the participant 
discontinues).  If the EOT visit coincides with a regular study visit, then the EOT evaluations 
will supersede those  of that scheduled visit, and the data should be entered in the EOT page in 
the eCRF.  If this decision does not coincide with a regular visit, reasonable efforts should be 
made to have the participant return to the site to have the EOT procedures complete d. 
8.8. Safety Follow -Up 
The safety follow -up period is the interval between the EOT visit ( EOT 1 or EOT2 , depending on 
the study period when the participant discontinues) and the scheduled safety follow -up visit, 
which should occur 30  (+ 7) days after the EOT v isit (or after the last dose of study drug if an 
EOT visit was not performed).  
Adverse events and SAEs must be reported up until 1) at least 30 days after the last dose of study 
drug or the date of the safety follow -up visit or 2) until toxicities resolve,  return to baseline, or 
are deemed irreversible, whichever is longer.  Reasonable efforts should be made to have the 
participant return for the safety follow -up visit and report any AEs that may occur during this 
period.  

Incyte Corporation   Page 45 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  9. ADVERSE EVENTS:  DEF INITIONS AND PR OCEDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of Adverse Event  
Adverse Event Definition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not it is considered drug -related.  
• An AE can  therefore be any unfavorable or unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. 
Additional Guidance for Event s Meeting t he Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease) are t o be reported as an AE.  
• Abnormal laboratory test results are to be reported as an AE if they are considered clinically 
meaningful, induce clinical signs or symptoms, require concomitant therapy, or require changes in 
study drug.  Whenever possible, a diagn osis (eg, anemia, thrombocytopenia) should be recorded in 
the eCRF rather than the abnormal laboratory test result (eg, low hemoglobin, platelet count 
decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition/disease, including either an  increase 
in the frequency and/or intensity of the condition, is to be reported as an AE.  
• New conditions detected or diagnosed after the start of study drug administration are to be reported 
as an AE.  
• Signs, symptoms, or the clinical sequelae of a suspecte d drug -drug interaction are to be reported as 
an AE.  
• Signs  and/or symptoms  from dosing erro rs of a study drug (eg, overdose) or a concomitant 
medication are to be reported as an AE.  
•  "disease progression ," or "failure of expected pharmac ological action " will not be 
reported as an AE or SAE .  . 
• A condition that leads to a medical or surgical procedure (eg, endoscopy, appendectomy) will be 
reported as an AE if it occurs after obtain ing informed consent.  If the condition is present before 
entering the study, then it should be captured as medical history.  
• Pre-existing diseases or conditions with expected fluctuations in signs or symptoms should be 
reported as an AE only if the investi gator judges the fluctuation to have worsened more than 
expected during study participation.  

Incyte Corporation   Page 46 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitaliz ation for signs/symptoms of the disease under study, death due 
to progression of disease).  
A serious adverse event is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term "life-threatening " in the definition of "serious " refers to an adverse drug experience that 
places the participant, in the opinion of the initial reporter, at immediate risk of death from the adverse 
experience as it occurs.  This does not include an adverse drug experience  that, had it occurred in a 
more severe form, might have caused death . 
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the participant has been detained (involving at least an 
overnight stay) at the hospital  or emergency ward for observation and/or treatment that would not have 
been appropriate in the physician 's office or outpati ent setting.  Complications that occur during 
hospitalization are AEs.  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious.  When in doubt as to whether hospitalization occurred or was necessary, the AE 
should be considered serious.  
Hospitalization for elective treatment or planned surgery (eg, stent replacement, hip surgery) is not 
considered an SAE.  
Hospitalization for medical interventions in which no unfavorable medical occurrence occurred 
(ie, electi ve procedures or routine medical visits) are not considered SAEs.  
d. Results in persistent or significant disability/incapacity  
• The term "disability " means a substantial disruption of a person 's ability to conduct normal life 
functions.  This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental 
trauma (eg,  sprained ankle), that may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is an important medical event  
An important medical event is an event that may not result in death, be immediately life -threatening, or 
require hospitalization but may be con sidered serious when, based on appropriate medical judgment, 
the event may jeopardize the participant and may require medical or surgical intervention to prevent 
one of the outcomes listed in the above definition.   Examples of such events include new invas ive or 
malignant cancers, intensive treatment in an emergency department or at home for allergic 
bronchospasm, blood dyscrasias, convulsions that do not result in hospitalization, development of drug 
dependency or drug abuse, or suspected transmission of a n infectious agent via a medicinal product.  
 
Incyte Corporation   Page 47 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event Form in the eCRF.  AEs/SAEs should be reported for randomized participants, but 
only SAEs need to be reported for screen failure participants.   For ra ndomized participants, 
conditions that were present at the time informed consent was given should be recorded on the 
Medical History Form in the eCRF.   For detailed information, refer to the eCRF guidelines.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospital progress notes, lab oratory reports, and diagnostic  reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptabl e for the investigator to send photocopies of the participant 's medical records in 
lieu of completing the Adverse Event Form in the eCRF.  
• There may be rare instances when copies of medical records for certain cases are requested.  In this 
case, all participant identifiers, with the exception of the participant number, will be redacted by the 
site staff on the copies of the medical records befo re submission .  These records can be submitted 
to Incyte Pharmacovigilance by email/fax per the contact information listed in the Study Manual or 
as per SAE completing guidelines.  
• The investigator will attempt to establish a diagnosis of the event based on  signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate  AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine  the following : 
• The severity grade (CTCAE  v5.0 Grade 1 to 5).  See below for further instructions on the 
assessment of intensity.  
• Whether there is at least a reasonable possibilit y that the AE is related to the study drug:  suspected 
(yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at  the final safety follow -up visit. 
• The action taken with re gard to study drug as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a concomitant medication 
or nondrug therapy, this action should be recorded on the Adverse Event Form, and the treatment 
should be specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and 
Non-Drug Therapy).  
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1  through 5.  If an event is not 
classified by CTCAE, the severity of the AE will be graded according to the scale below to estimate the 
grade of severity.  
Incyte Corporation   Page 48 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
treatment not indicated.  
• Grade 2:   Moderate; minimal, local, or noninvasive treatment indicated; limiting age -
appropria te activities of daily living.  
• Grade 3:   Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care activities of daily 
living.  
• Grade 4:   Life-threatening consequences; urgent treatment indicated.  
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study drug and each occurrence of 
each AE/SAE.   
• A "reasonable possibility " of a relationship conveys that there are medical facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the possibility of a relatio nship.  
• The investigator will also consult the RSI in the IB for study drug in making his/her assessment.  
• Alternative causes, such as underlying or concurrent disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of t he event to study drug administration, will be 
considered and investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report.  However, the causality assessment is one of the criteria 
used when determining regulatory reporting requ irements.  Therefore, it is very important that 
the investigator always make an assessment of causality based on the available information 
for every event before the initial transmission of the SAE.  
− The investigator may change his/her opinion of causality in light of follow -up information and 
submit the updated causality assessment.  
Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by the sponsor to elucidate the nature 
and/or causality of the AE or SAE as fully as possible.  This may include additional laboratory tests 
or investigations, histopathological examinations, or consultation with other h ealth care 
professionals.  
• Once an AE is detected, it should be followed in the AE eCRFs until it has resolved or until it is 
judged to be permanent; assessment should be made at each visit (or more frequently if necessary) of 
any changes in severity, the s uspected relationship to the stu dy drug, the interve ntions required to 
treat the event, and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg, between visits), each 
change in severity will be reported as a separate AE . 
Incyte Corporation   Page 49 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • If a participant dies during participation in the study or during a recognized follow -up period, the 
investigator will provide the sponsor with a copy of any postmortem findings , including 
histopathology.  
• Updat ed SAE information will be recorded in the originally completed eCRF  and reported to Incyte 
Pharmacovigilance ( either via email/fax if paper SAE form is used or in the SAE EDC CRF ) until 
resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -up. 
• Any update d SAE data (including SAEs being downgraded to nonserious) will be submitted to the 
sponsor (or designee) within 24  hours of receipt of the information.  
9.4. Reporting of Serious Adverse Events  
Regar dless of suspected causality (eg , relationship to study drug or study procedure[s]), all SAEs 
occurring after the participant has signed the ICF through the last study visit (or 30 days after the 
last dose of study drug, whichever occurs later) must be reported to the sponsor (or designe e) 
immediately, without undue delay, under no circumstances later than 24 hours  following 
knowledge of the event . 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation.  However, if the investiga tor learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers it is at least 
reasonably possible that the event is related to the study drug or study participation, then the 
investigator must notify the sponsor (or designee) immediately, without undue delay, under no 
circumstances later than 24 hours f ollowing knowledge of the event . 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at sub sequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of a study 
drug under clinical investigation are met.  
If the SAE is not documented in the  RSI of the  IB for the study drug (new occurrence) and is 
thought to be related to the study drug, the sponsor or its designee may urgently require further 
information from the investigator for reporting to health authorities.  The sponsor or its designee 
may need to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported.  Suspecte d unexpected serious adverse 
reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory requirements 
in participating countries.  
The sponsor has  a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation.  The sponsor 
will comply with country -specific regulatory requirements relating to safety rep orting to the 
regulatory authority, IRB/IEC, and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
Incyte Corporation   Page 50 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  An investigator who receives an investigator safety report describing a n SAE or other specific 
safety information ( eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB and will notify the IRB/IEC, if ap propriate according to local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event Form in the eCRF.  
• The investigator must also complete the Incyte Serious Adverse Event Report Form in Engl ish.   
• Follow -up information is also recorded and transmitted to Incyte Pharmacovigilance on an 
amended or new Serious Adverse Event Report Form, with an indication that it is follow -up to the 
previously reported SAE and the date of the original report.  T he follow -up report should include 
information that was not provided on the previous Serious Adverse Event Report Form, such as the 
outcome of the event (eg, resolved or ongoing), treatment provided, action taken with study drug 
because of the SAE (eg, dos e reduced, interrupted, or discontinued), or participant disposition (eg, 
continued or withdrew from study participation).  Each recurrence, complication, or progression of 
the original event should be reported as follow -up to that event, regardless of whe n it occurs.  
• Contacts for SAE reporting can be found in the Study Manual.  
9.5. Events of Clinical Interest  
Not applicable.  
9.5.1.  Adverse Events of Special Interest  
Not applicable . 
9.6. Emergency Unblinding of Treatment Assignment  
In a medical emergency during the double -blind, vehicle -controlled period, if the investigator 
deems it necessary to determine optimal medical management of the participant, emergency 
unblinding will be performed exclusively by the principal investigator and subinvestigator as 
described in the IRT Study Manual.  The IRT system has an option to select for "Emergency 
Code Break " action for a given participant.  After entering the 6 -digit study drug tube number 
and verification of the unmasking in formation, the investigator/subinvestigator will proceed to 
either final confirmation or cancellation of the code break procedure.  
If a participant 's treatment assignment is unblinded, the sponsor or its designee must be notified 
immediately by telephone , followed  up with an email.  
If an investigator, site personnel performing assessments, or participant is unblinded, the 
participant must discontinue  study drug unless there are ethical reasons to have the participant 
remain on the study drug.  In these cas es, the investigator must obtain specific approval from the 
sponsor 's (or its designee 's) medical monitor for the participant to continue in the study . 
Incyte Corporation   Page 51 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  9.7. Pregnancy  
Pregnancy, in and of itself, is not regarded as an AE unless there is suspicion that the study  drug 
may have interfered with the effectiveness of a contraceptive medication or method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensu re safety:  
• The study drug must be discontinued immediat ely (female participants only).  
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on f etal outcome are collected for regulatory reporting and drug safety evaluation.  
Follow -up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any  birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by following until the first 
well-baby visit.  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by the investigator to the sponsor or its design ee.  Pregnancy follow -up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor 's study drug to any pregnancy outcome, as well as follow -up to the first well -baby 
visit or the dur ation specified in local regulations, whichever is later.  Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or its designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant 's partner, the event should be reported to the spons or on the Clinical Trial 
Pregnancy Form.  
9.8. Warnings and Precautions  
Special warnings or precautions for the study drug, derived from safety information collected by 
the sponsor or its designee, are presented in the IB.  Additional safety information collected 
between IB updates will be communicated in the form of Investigator Notifications.  Any 
important new safety information should be discussed with the participant during the study as 
necessary.  If new significant r isks are identified, they will be added to the ICF.  
9.9. Product Complaints  
The sponsor collects product complaints on study drugs and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facil itate 
process and product improvements.  
All product complaints associated with material packaged, labeled, and released by the sponsor 
or its designee will be reported to the sponsor.  All product complaints associated with other 
study material will be rep orted directly to the respective manufacturer.  
Incyte Corporation   Page 52 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact or respective 
manufacturer as n oted in the packaging information.  Any AE associated with a product 
complaint should be recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product.  
9.10. Treatment of Overdose  
There has been no clinical experience with overdose of ruxolitinib cream.  Treatment of 
overdose shou ld consist of general supportive measures.  
10. STATISTICS  
10.1. Sample Size Determination  
Due to the exploratory nature of the study, the sample size is not only based on calculation of 
statistical power.  The sample size is considered to be sufficient to obtain ade quate  
safety, tolerability,  data to achieve the objectives of the study.  
Approximately 60 participants will be randomized 2:1 to ruxolitinib cream 1.5% BID or vehicle 
BID to ensure approximately 45 participants will have multiple biomarker  data (e g, CXCL10) 
available at Week 24.  
On the basis of  the results of a Phase 2 study (INCB  18424 -211), the anticipated  difference in 
percentage of change from baseline in CXCL10 between ruxolitinib cream 1.5%  BID and 
vehicle is 22% ( standard deviation = 0.25%).  Using a 2-sample t -test, the sample size of 45 will 
provide great power ( ≥ 80%) to detect such difference with a 2 -sided  alpha of  0.10.  
10.2. Populations for Analysis  
The populations for analysis are provided in Table  9. 
Table  9: Populations for Analysis  
Population  Description  
ITT The ITT population includes all randomized participants.  Treatment groups for 
this population will be defined according to the treatment assignment at 
randomization.  
Safety  The safety population includes all participants who applied at least 1  dose of 
study drug.  Treatment groups for this population will be determined according to  
the actual treatment the participant received on Day 1.  

Incyte Corporation   Page 53 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  10.3. Level of Significance  
Not applicable.  
10.4. Data Handling Definitions a nd Conventions  
10.4.1.  Day 1  
Day 1  is the date that the first application of ruxolitinib cream or vehicle cream is administered 
to the participants . 
For randomized participant s not treated with any study drug, Day 1 is defined as the day of 
randomization .  
10.4.2.  Study Day  
If a visit/reporting da te is on or after Day 1, then the study day at the visit/reporting date will be 
calculated as  
Day # = (Visit/Reporting Date – Day 1 date + 1).  
If the visit/reporting date is before Day 1, then the study day at the visit/reporting date will be 
calculated as  
Day # = (Visi t/Reporting Date – Day 1 date).  
A study day of −1 indicates 1  day before Day 1.  
10.4.3.  Baseline Value  
Baseline is the last nonmissing measurement obtained before or on the day of first application of 
ruxolitinib cream or vehicle cream.  
For randomized participant s not treated with any study drug, baseline is defined as the last 
nonmissing assessment before or on the day of randomization for all parameters.  
10.4.4.  Handling of Missing and Incomplete Data  
In general, missing data will not be impute d. 
10.5. Statistical Analyses  
10.5.1.  Baseline, Demographics, Disease History , and Prior and Concomitant 
Medication  
The following demographics will be summarized for the ITT population: age, age group, sex, 
race, ethnicity, region, weight, height, and body mass index . 
Baseline disease characteristics, prior medications for vitiligo, medical history , and prior and 
concomitant medications  will be summarized by treatment group.  
10.5.2.  Disposition of Participants  
The number and percentage of participants  who were enrolled, rando mized, treated, and 
completed for each period will be summarized for the ITT population.  
Incyte Corporation   Page 54 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  10.5.3.  Exposure  and Study Drug Compliance    
For participants in the ITT  population , descriptive statistics will be provided for duration of 
treatment, average daily dose, tot al dose, and study drug compliance.  
  
 
 
 
 
10.5.5.  Safety Analysis  
Safety is being evaluated as a secondary objective in this study.  Safety analyses will be 
conducted using the safety population  and are summarized in  Table  10. 
Table  10: Safety Analyses  
Objective  Statistical Analysis Methods  
To assess the safety 
and local tolerability 
of ruxolitinib cream.  Adverse Events  
A TEAE is any AE either reported for the first time or worsening of a pre -existing event 
after first dose of study drug.  Analysis of AEs will be limited to TEAEs, but data 
listings will include all AEs regardless of their timing to study drug administration.  
Adverse events will be coded using MedDRA and tabulated by preferred term and 
system organ class.  Severity of AEs will be based on the CTCAE v5.0 using Grades 1 
through 5.  
The subset of AEs considered by the investigator to have a relatio nship to study drug 
will be considered to be treatment -related AEs.  If the investigator does not specify the 
relationship of the AE to study drug, then the AE will be considered treatment -related.  
The incidence of AEs and treatment -related AEs will be ta bulated.  
Clinical Laboratory Tests  
Actual values and changes from baseline in clinical laboratory test results will be 
summarized using descriptive statistics.  Laboratory test values outside the normal 
range will be assessed for severity based on the norm al ranges for the clinical reference 
laboratory.  The incidence of abnormal laboratory values will be tabulated.  
Laboratory data will be classified into Grades 1 through 5 using CTCAE v5.0.  The 
following summaries will be produced for the laboratory data:  
• Number and percentage of participants with worst postbaseline CTCAE grade 
(regardless of baseline value).  Each participant will be counted only for the worst 
grade observed postbaseline.  
• Shift tables from baseline to the worst postbaseline value using CTCAE grade.  
• For laboratory parameters where CTCAE grades are not defined, shift tables to the 
worst postbaseline value using the low/normal/high classifications based on 
laboratory reference ranges.  
Vital Signs  
Descriptive statistics and mean change from baseline will be determined for vital signs 
(blood pressure, pulse, respiratory rate, and body temperature) at each assessment time.  
Electrocardiograms  
Descriptive statistics and mean change from baseline will be determined for each ECG 
parameter at each a ssessment time.  

Incyte Corporation   Page 55 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  10.5.6.  Translational  Analyses  
Translational endpoints are listed in Section  3.  These are being evaluated as primary, secondary, 
 objectives.   Details of translational analyses will be provided in the Statistical 
Analysis Plan.  
10.6. Interim Analysis  
No formal interim analysis is planned in this study.  The primary analysis will occur after the 
primary database lock, when all participants have completed the vehicle -controlled, double -blind 
treatment period.  The s ponsor will be unblinded , while investigators and participants will still be 
blinded , to the study treatment after the primary database lock.  After Week 52, investigators and 
participants will be unblinded.  
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Resp onsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by the investigator and 
reviewed and approved by the IRB/IEC before the study is initiated.  
• The investigator is respo nsible for ensuring that the safety reports provided by the 
sponsor are reviewed and processed in accordance with regulatory requirements, the 
policies and procedures established by the IRB/IEC, and institutional requirements.  
• Any amendments to the Protoco l will require  approval from  both Health Authorities 
and IRB/IEC before implementation of changes made to the study design, except for 
changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the fo llowing:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC.  
− Notifying the IRB/IEC of SAEs or other significant safety f indings as required by 
IRB/IEC procedures.  

Incyte Corporation   Page 56 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  − Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations.  
• Adhering to the Protocol as  described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by the sponsor or its designee and, second, by the 
IRB/IEC.  Each investigator is responsibl e for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws but for a 
minimum period of at least 2  years after the last marketing application approval in an 
ICH region and until there are no pending or contemplated marketing applications in 
an ICH region, or if not approved, 2  years after the termination of the test article for 
investigation to ensure the availability of study documentation should it become 
neces sary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event of acciden tal loss or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contacted to arrange alternative record storage options.  
− All eCRF data entered by the site (includi ng audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and audit trai l. 
11.2. Data Management  
Data management will be performed in a validated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion guidelines  for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan 's requiremen ts.  Other data outside the EDC system required in the study conduct 
of the Protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors and , as designated by the sponsor, will have their own da ta flow 
management plans, study charters, or biomarker plans, as applicable.  
The sponsor (or designee) will be responsible for:  
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ong oing source data verification to confirm that 
data entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved Protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
Incyte Corporation   Page 57 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • Managing and reconciling the data generated, and/or collected including documents 
and results such as laborato ry or imaging data analyzed centrally by a designated 
vendor of the sponsor.  
The investigator will be responsible for:  
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the delivery of, all other results, documents, data, know -how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, biomarker data, photographs, diary data), 
or as otherwise speci fied in the Protoc ol. 
• Maintaining adequate and accurate source documents and trial records that include all 
pertinent observations on each of the site 's trial participants.  Source data should be 
attributable, legible, contemporaneous, original, accurate, and complete.  Changes to 
source data should be traceable, should not obscure the original entry, and should be 
explained if necessary (e.g., via an audit trail).   Source data are in general all 
information in original records and certified copies of original records of cli nical 
findings, observations, or other activities in a clinical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source 
documents (original records or certified copies).   
• Verifying that data entries are accu rate and correct by physically or electronically 
signing the eCRF.  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, or sent to a central vendor designated by the sponsor, or as 
described in other study and  data flow manuals.  
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed and 
available at the investigator 's site.   Example s of source documents are original 
documents, data, and records (e.g., hospital records, electronic hospital records, 
clinical and office charts, labor atory notes, memoranda, participants ' diaries or 
evaluation checklists, pharmacy dispensing records, recorded d ata from 
automated instruments, copies or transcriptions certified after verification as being 
accurate copies, microfiches, photographic negatives, microfilm or  magnetic 
media, x -rays, participants ' files, and e-records/ records kept at the pharmacy, at 
the laboratories and at medico -technical departments involved in the clinical 
trial).   
− Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator  may need to request previous medical records or transfer records, 
depending on the study.  Current applicable medical records must be available.  
• Sending participants ' data, either as unique samples, or copies, or photographs, to be 
evaluated centrally or analyzed centrally, or both, by a qualified vendor designated by 
the sponsor.  
Incyte Corporation   Page 58 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  • Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by providing direct access to source data and other relevant clinical study 
docum ents. 
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  T he 
investigator must allow the auditors to review original source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of  an investigational 
product.  The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other 
study -related documents.  The investigator must immediately notify the sponsor 
when contacted by any regulatory authority for the purposes of conducting an 
inspection.  
11.3. Data Privacy and Confidentiality  of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data protection laws 
and regulations .  The i nvestigator and the sponsor or its designee are responsible for ensuring 
that sensitive personal information is handled in accordance with local data protection laws 
(including but not limited to  HIPAA  and GDPR ) as applicable .  Appropriate consent for 
collection, use and disclosure and/or transfer (if applicable) of personal information must be 
obtained  in accordance with local data protection laws . 
Participant names will not be supplied to the sponsor or its designee .  Only the participant 
number will be r ecorded in the eCRF; if the participant 's name appears on any other document 
(eg, laboratory report), it must be obliterated on the copy of the document to be supplied to the 
sponsor or its designee .  Study findings stored on a computer will be stored in a ccordance with 
appropriate technical and organizational measures as required by local data protection laws . 
11.4. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies subject  to FDA 
Regulation Title 21 CFR Part 54 – Financial Disclosure by Clinical Investigators (ie, "covered 
studies ") are required to submit a completed Clinical Investigator Financial Disclosure form that 
sufficiently details any financial interests and arrange ments that apply .  For the purpose of this 
regulation, "clinical investigator " is defined as any investigator or subinvestigator who is directly 
involved in the treatment or evaluation of research participants, including the spouse and each 
dependent child  of the clinical investigator or subinvestigator .  These requirements apply to both 
US and foreign clinical investigators conducting covered clinical studies.  
Incyte Corporation   Page 59 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form .  During a covered clinical study, 
any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee .  At the conclusion of the c overed clinical study, the 
clinical investigators will be reminded of their obligations .  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the finan cial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study.  
11.5. Publication Policy  
By signing the study Protocol, the investigator and his /her institution ag ree that the results of the 
study may be used by the sponsor, Incyte Corporation (Incyte), for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals.  Study results will be publis hed in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator 's name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study results 
are cont ained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by the sponsor or its designee.  
The results of this study may be published or presented at scientific meetings .  If this is foreseen, 
the investigator agre es to submit all manuscripts or abstracts to the sponsor before submission .  
This allows the sponsor to protect proprietary information and to provide comments . 
The sponsor will comply with the requirements for publication of study results .  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data .  In this case, a 
coordinating investigator will be designated by mutual agreement.  
Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.6. Study and Site Closure  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor .  Study sites will be closed upon study 
completion .  A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The in vestigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but a re 
not limited to:  
• Failure of the investigator to comply with the Protocol , the requirements of the 
IRB/IEC or local health authorities, the sponsor 's procedures, or GCP guidelines . 
• Inadequate recruitment of participants by the investigator . 
• Discontinuatio n of further study treatment  development . 
Incyte Corporation   Page 60 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  12. REFERENCES  
Clinical Trials Facilitation and Coordination Group. Recommendations related to contraception 
and pregnancy testing in clinical trials. 20 14. 
Dina Y, McKesey J, Pandya AG. Disorders of hypopigmentation. J Drugs Dermatol 
2019;18:s115 -s116.  
European Medicines Agency. Guidance on the Management of Clinical Trials During the 
COVID -19 (Coronavirus) Pandemic. 2020.  
González U, Whitton M, Eleftheriadou V, Pinart M, Batchelor J, Leonardi -Bee J. Guidelines for 
designing and reporting clinical trials in vitiligo. Arch  Dermatol 2011;147:1428 -1436.  
 
 
 
 
 
 
Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. 
Front Immunol 2019;10:2342.   
Krüger  C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in 
children/adolescents and adults. Int J Dermatol 2012;51:1206 -1212.  
Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and 
maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med 2014;6:223ra23.  
Rashighi M, Harris JE. Interfering with the IFN -γ/CXCL10 pathway to develop new targeted 
treatments for vitiligo. Ann Transl Med 2015;3:343.  
Rosmarin D, Pandya AG, Lebwohl M, et al.  Ruxolitinib cream for treatment of vitiligo: a 
randomised, controll ed, phase 2 trial. Lancet 2020; 396:110 -120. 
Ruxolitinib Cream Investigator 's Brochure. Wilmington, DE: Incyte Corporation.  
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160 -169. 
van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin 
melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 
2009;129:2220 -2232.  
World Health Organization. WHO Model Prescribing Information: Drugs Us ed in Skin Diseases. 
1997.  
 

Incyte Corporation   Page 61 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  APPENDIX  A. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S AND DEFINITIONS  
For male participants in the study:  
Male participants should use a condom during treatment through 90 days after the end of systemic 
exposure.  If the male participant has a partner that is of childbearing potential, the partner should also 
use contraception through 90 days after the end of relevant systemic exposure.  In addition, male 
particip ants must refrain from donating sperm during the study through 90 days after the end of 
relevant systemic exposure.  Male  participant s who have had a vasectomy qualify as having met the 
requirement for a highly effective birth control method.  
For female p articipants in the study:  
The following methods that can achieve a failure rate of < 1% per year when used consistently and 
correctly are considered as highly effective birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation  
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation  
− oral 
− injectable  
− implantablea 
• Intrauterine devicea 
• Intrauterine hormone -releasing systema 
• Bilateral tubal occlusiona 
• Vasec tomized partnerab 
• Sexual abstinencec 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:d 
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action  
• Male or female condom with or without spermicidee 
• Cap, diaphragm, or sponge with spermicidee 
• Tubal ligation  
a Contraception methods that in the context of this guidance are considered to have low user dependency.  
b Vasectomized partner is a highly effective method of avoiding pregnancy provided that the partner is the sole 
sexual partner of the woman of childbearing  potential study participant and that the vasectomized partner has 
received medical assessment of the surgical success.  
c In the context of this guidance, sexual abstinence is considered a highly  effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical stu dy and the 
preferred and usual lifestyle of the participant.  
d Choices are for US and Canada participants only and include above < 1% failure rate methods.  
e Combination s of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) are 
also considered acceptable, but not highly effective, birth control methods.  
Source:  Clinical Trials Facilitation and Coordination Group 2014 . 
Incyte Corporation   Page 62 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  APPENDIX  B. WHO CLASSIFICATION OF TO PICAL 
CORTICOSTEROIDS  
Hydrocortisone and betamethasone are examples of low - and high -potency topical 
corticosteroids.  Topical corticosteroids have been ranked in terms of potency into 4 groups 
consisting of 7 classes.  Class I topical corticosteroids are the most potent, and Class VII are the 
least potent.  Efficacy and side  effects are greatest with the Class I ultra -high–potency 
preparations, which  should only be used for limited time periods (2 -3 weeks).  Representative 
preparations by group are listed in the table below.  These groups may vary depending on the 
formulation and concentration and should be considered approximate.  In general, ointmen ts are 
more potent than creams or lotions.  Potency is also increased when topical corticosteroids are 
used under occlusive dressings or in intertriginous areas.  
Potency  Class  Topical Corticosteroid  Formulation  
Ultra high  I Clobetasol propionate  Cream, 0.05%  
Diflorasone diacetate  Ointment, 0.05%  
High  II Amcinonide  Ointment, 0.1%  
Betamethasone dipropionate  Ointment, 0.05%  
Desoximetasone  Cream or ointment, 0.025%  
Fluocinonide  Cream, ointment or gel, 0.05%  
Halcinonide  Cream, 0.1%  
III Betamethasone dipropionate  Cream, 0.05%  
Betamethasone valerate  Ointment, 0.1%  
Diflorasone diacetate  Cream, 0.05%  
Triamcinolone acetonide  Ointment, 0.1%  
Moderate  IV Desoximetasone  Cream, 0.05%  
Fluocinolone acetonide  Ointment, 0.025%  
Fludroxycortide  Ointment, 0.05%  
Hydrocortisone valerate  Ointment, 0.2%  
Triamcinolone acetonide  Cream, 0.1%  
V Betamethasone dipropionate  Lotion, 0.02%  
Betamethasone valerate  Cream, 0.1%  
Fluocinolone acetonide  Cream, 0.025%  
Fludroxycortide  Cream, 0.05%  
Hydrocortisone butyrate  Cream, 0.1%  
Hydrocortisone valerate  Cream, 0.2%  
Triamcinolone acetonide  Lotion, 0.1%  
Low VI Betamethasone valerate  Lotion, 0.05%  
Desonide  Cream, 0.05%  
Fluocinolone acetonide  Solution, 0.01%  
VII Dexamethasone sodium phosphate  Cream, 0.1%  
Hydrocortisone acetate  Cream, 1%  
Methylprednisolone acetate  Cream, 0.25%  
Source:  WHO 1997 . 
 
Incyte Corporation   Page 63 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Incyte Corporation   Page 64 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL   
 
 
 
 

Incyte Corporation   Page 65 of 65 
Protocol INCB 18424 -214 Version 1  03 MAR  2021  
VV-CLIN -011898  CONFIDENTIAL  APPENDIX  D. PROTOCOL AMENDMENT S UMMARY OF CHANGES  
Not applicable.  
Signature Page for VV-CLIN-011898 v3.0
Signature Page for VV-CLIN-011898 v3.0Approval
Approver
03-Mar-2021 17:02:15 GMT+0000
Approval
Approver
03-Mar-2021 17:08:12 GMT+0000
Approval
Approver
03-Mar-2021 17:14:13 GMT+0000
Approval
Approver
03-Mar-2021 17:19:42 GMT+0000
Approval
Approver
03-Mar-2021 19:00:43 GMT+0000
